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c-MYC is a major oncogene involved in human cancer. Here, I have identified 
BPTF as a novel interactor of c-MYC required for its biological functions. This 
interaction is crucial for c-MYC transcriptional activity: BPTF knock-down leads to 
a decrease in c-MYC binding to DNA, changes in chromatin accessibility, and 
impaired activation of the c-MYC transcriptional program. In murine embryonic 
fibroblasts, BPTF is necessary for c-MYC-driven proliferation, G1-S progression, 
and replication stress, but not for c-MYC-induced apoptosis. Moreover, BPTF is 
critical for reprogramming of somatic cells into induced pluripotent stem cells 
using the four Yamanaka factors. In agreement with these findings, BPTF is 
required for the proliferation of c-MYC-addicted cancer cells and in human 
tumors its expression positively correlates with the activation of c-MYC gene 
signatures.  
To determine whether BPTF is required for the oncogenic effects of c-MYC, we 
used two genetic mouse models: Ela-Myc and E-Myc. Ela-Myc mice develop 
aggressive acinar and ductal tumors. While BPTF is dispensable for normal 
pancreatic development and differentiation, its embryonic inactivation in Ela-
Myc mice is associated with extensive loss of acinar cells. Moreover, deletion of 
BPTF in young Ela-Myc via activation of the Ptf1a-CreERT2 recombinase results in 
a significant delay in tumor onset and a corresponding extension in disease-free 
survival. c-MYC overexpression in the B cell lineage (E-Myc) leads to the 
development of Burkitt-like lymphomas. Inactivation of one Bptf allele does not 
impair B cell maturation but completely blocks lymphoma development. These 
findings underscore the importance of a more detailed study of BPTF function in 










c-MYC es uno de los principales oncogenes implicados en el cáncer humano. En 
el presente trabajo he identificado a BPTF como un nuevo interactor de c-MYC 
que además es requerido para sus funciones biológicas. Esta interacción es crucial 
para la actividad transcripcional de c-MYC: el knock-down de BPTF se acompaña 
de una disminución de la unión de c-MYC al DNA, cambios en la accesibilidad de 
la cromatina y de una inadecuada activación del programa transcripcional de c-
MYC. En fibroblastos embrionarios de ratón, BPTF es necesario para la 
proliferación, progresión G1-S y estrés replicativo dirigidos por c-MYC, pero no 
para la apoptosis instruida por el mismo. Además, BPTF es crítico para la 
reprogramación de células somáticas a células madre pluripotentes por medio de 
los cuatro factores descritos por Yamanaka. De acuerdo con estas observaciones, 
BPTF es necesario para la proliferación de líneas cancerosas adictas a c-MYC, y en 
tumores humanos su expresión correlaciona positivamente con la activación de 
los programas de expresión génica dirigidos por c-MYC.  
Con el objetivo de determinar si BPTF es necesario para los efectos oncogénicos 
de c-MYC, hemos usado dos modelos genéticos de ratón: Ela-Myc y E-Myc. Los 
ratones Ela-Myc desarrollan tumores acinares y ductales muy agresivos. Aunque 
BPTF es dispensable para la diferenciación y desarrollo pancreáticos normales, su 
inactivación embrionaria en ratones Ela-Myc se asocia con una extensa pérdida 
de células acinares. Además, la depleción de BPTF en ratones Ela-Myc jóvenes por 
medio de la recombinasa Ptf1a-CreERT2 resulta en un retraso significativo en la 
aparición de los tumores y en una consiguiente extensión de la supervivencia libre 
de enfermedad. La sobre-expresión de c-MYC en el compartimento de células B 
conduce al desarrollo de linfomas que reproducen la enfermedad del Linfoma de 
Burkitt. La inactivación de una sola copia de Bptf no afecta a la maduración de las 
células B pero bloquea por completo la formación de tumores. Estas 
observaciones destacan la importancia de un estudio más detallado de la función 
de BPTF en mamíferos y subrayan el potencial de explotar el eje c-MYC:BPTF 
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1. THE ROLE OF CHROMATIN DURING TRANSCRIPTION 
1.1. Nucleosomes are the basic unit of chromatin 
Chromatin is the complex of DNA, histones, and non-histone proteins from 
which eukaryotic chromosomes are formed. The nucleosome is the primary unit 
of chromatin and is composed of 147 bp of DNA wrapped 1.65 times around an 
octamer of the four core histones (H2A, H2B, H3, and H4). Structurally, core 
histones are relatively small proteins with a globular domain (the histone fold) 
and two N-terminal “tails”. Consecutive nucleosome core particles are separated 
by unwrapped linker DNA of variable length (20-90 bp). In addition, one molecule 
of histone H1 associates at the position where the DNA enters and exits the 
nucleosome core, thus sealing the two turns of DNA (Laybourn and Kadonaga 
1991). The multiple contact points between histones and DNA make the 
nucleosome a very stable complex and, for this reason, it is well suited for its 
packaging function. Nonetheless, its role extends beyond DNA compaction and 
occlusion. Nucleosomes are also dynamic participants in chromatin-directed 
processes such as transcription, replication, DNA repair, kinetochore and 
centromere construction, and telomere maintenance (Saha et al. 2006). Cells 
modulate the way chromatin is packed in order to regulate such processes. This 
involves the dynamic competition between nucleosomes and DNA-binding 
factors for regulatory sequences in the DNA (Li et al. 2007). This competition is 
mainly influenced by three different types of protein complexes. One family 
includes ATP-dependent remodelling complexes that weaken DNA-histone 
interactions, thereby facilitating nucleosome repositioning, reconfiguration or 
ejection (Kingston and Narlikar 1999). Another family includes chromatin-
modifying enzymes that add or remove covalent modifications at particular 
residues within histones. The third family is constituted by the DNA 
methyltransferases (DNMTs) that methylate cytosines within CpG dinucleotides 
and thus regulate transcription, high-order chromatin structures and genome 
syability (Espada and Esteller 2010). Of note, histone modifying complexes and 
DNMTs work in concert with chromatin-remodelling complexes. Thus, the 
chromatin fibre is a dynamic and flexible structure that continuously changes in 
response to a wide range of biological inputs (Zhang and Reinberg 2001). 
The linear string of nucleosomes (“beads on a string”) is further packed into a 
30-nm fibre where nucleosomes are arranged in a spiral or solenoid (Hayes and 
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Hansen 2001). The histone tails, although dispensable for the formation of the 
nucleosome, are required for inter-nucleosomal interactions and, together with 
histone H1, help condensing the DNA (Luger et al. 1997). Additional levels of 
compaction enable these fibres to be packaged into the small volume of the 
nucleus (Fig. 1). 
 
Figure 1. Schematic view of the 30-nm fibre. Sequence-specific DNA-binding factors 
bind to accessible regions in the linker DNA, the edge of the nucleosome or in 
remodelled nucleosomes. Regions of chromatin that are nucleosome-free or contain 
remodelled nucleosomes can often be detected experimentally by the unusually high 
susceptibility of their DNA to digestion by nucleases - as compared with the DNA in 
nucleosomes. Adapted from Alberts et al 2002. 
 
1.2. Histone covalent modifications 
Core histones are susceptible to a wide variety of post-translational 
modifications (up to 130), including methylation, acetylation, ubiquitination, 
ADP-ribosylation, sumoylation or phosphorylation (Kouzarides 2007; Tan et al. 
2011) (Table 1). The majority of modifications take place at the N-terminal tails 
of histones, with a few exceptions occurring within the globular regions (e.g. 
phosphorylation of H3Y41) (Dawson et al. 2009). The distribution of these 
modifications is tightly regulated and is crucial for their functional outcome.  
Histone modifications serve two main functions. First (with the exception of 
methylation), they alter the net charge of histones and thus enhance or loosen 
the non-covalent interactions within and between nucleosomes. Second, they 
serve as docking sites for the recruitment of epigenetic readers with unique 
domains that specifically recognize these modifications. These chromatin readers 
recruit in turn additional chromatin modifiers and remodelling enzymes, which 
perform diverse chromatin functions (Dawson and Kouzarides 2012). 
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It has been suggested that histone modifications act sequentially or in 
combination to form a ‘histone code’ that determines the downstream events 
(Strahl and Allis 2000).  
 
Table 1. Histone modifications, writers, readers and their function. Modifications: me1, 
mono-methylation; me2, di-methylation; me3, tri-methylation; me2s, symmetrical di-
methylation; me2a, asymmetrical di-methylation; Cit, citrulline. Reader domains: MBD, 
methyl-CpG-binding domain; PHD, plant homeodomain; MBT, malignant brain tumor 
domain; PWWP, proline-tryptophan-tryptophan-proline domain; BRCT, BRCA1 C-
terminus domain; UIM, ubiquitin interaction motif; IUIM, inverted ubiquitin interaction 
motif; SIM, sumo interaction motif; PBZ, poly ADP-ribose binding zinc finger. Adapted 
from Dawson and Kouzarides 2012; Kouzarides 2007; and Bannister and Kouzarides 
2011. 
 
1.3. Chromatin remodelling 
ATP-dependent chromatin remodelling enzymes disrupt DNA-histone contacts 
and, as a result, mobilize, evict or exchange histones. They operate in the context 
of multisubunit complexes, which have been divided into four major families 
according to their biochemical activity and subunit composition. Each of these 
families has a different mechanism of action and is composed of members with 
multiple chromatin reader motifs (e.g. bromodomains) that confer some 
specificity to their remodelling activities (Wang et al. 2007).    
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1. ISWI (Imitation Switch): With the exception of NURF and Iswi1, ISWI 
remodelling complexes slide nucleosomes in an orderly manner to repress gene 
transcription (Badenhorst et al. 2002; Morillon et al. 2003). In addition, they play 
key roles in chromatin assembly after DNA replication and maintenance of 
higher-order chromatin structures (Erdel and Rippe 2011).  
2. SWI/SNF (SWItching defective/Sucrose Non-Fermenting): SWI complexes 
catalyse the sliding or ejection of nucleosomes (in part or as a whole) with the 
help of histone chaperones. Their function correlates with nucleosome 
disorganization, increased accessibility for transcription factor binding, and gene 
activation (Saha et al. 2006). Members of this family have also been implicated in 
DNA repair following DNA damage (Chai et al. 2005; Shim et al. 2007). 
3. INO80/SWR1 (INositol requiring 80): INO80 complexes have both activating 
and repressive effects on gene transcription. SWR1 complexes promote the 
incorporation of the histone variant H2A.Z into nucleosomes in a replication-
independent manner (Mizuguchi et al. 2004). H2A.Z differs from canonical H2A 
in its amino acid sequence and stability, which depends on the histone H3 
subtype present in the histone octamer. Hybrid nucleosomes containing both 
H2A.Z and the histone variant H3.3 are more unstable and prone to movement 
or ejection by chromatin remodellers (Jin and Felsenfeld 2007). In human cells, 
H2A.Z is preferentially enriched at poised promoters. Upon transcriptional 
activation, H2A.Z is rapidly evicted and its loss is required for full transcription 
(Zhang et al. 2005). 
4. NuRD/Mi-2/CHD (Nucleosome Remodelling and Deacetylation/Mi-2/ 
Chromodomain Helicase DNA-binding): Members of this family primarily mediate 
transcriptional repression. 
 
1.4. Histone variants 
Nucleosomes are constructed from the four canonical histones (H2A, H2B, H3, 
and H4) or, alternatively, from histone variants with specific expression, 
localization, and species-distribution patterns (e.g. H3.3, macroH2A, H2A.Z, 
H2ABbd or H2A.X) (Kamakaka and Biggins 2005).  
The genes encoding the four canonical histones cluster together in the genome 
and are transcribed during S phase. Conversely, genes encoding non-canonical 
histones are found singly in the genome and are constitutively expressed. Histone 
variants differ in their primary amino acid sequence from their canonical 
paralogues. These differences impact on their structure, intrinsic stability, the 
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length of DNA they wrap and even the direction of wrapping (Talbert and Henikoff 
2010).  
Whereas canonical histones function primarily in genome packaging and gene 
regulation; histone variants participate in a wide range of biological processes 
such as DNA repair, recombination, chromosome segregation, transcription, sex 
chromosome condensation, and sperm chromatin packaging. 
 
1.5. Transcription in the chromatin context 
Chromatin imposes significant obstacles on all aspects of transcription mediated 
by RNA Pol II, from initiation to elongation. In order for transcription to occur, 
chromatin structure is modulated through multiple mechanisms, including 
histone modification, eviction or reconfiguration, and chromatin remodelling. 
The prototypical RNA Pol II transcription cycle begins with the binding of 
sequence-specific activating transcription factors upstream of the core promoter. 
The binding sites for these activators are primarily found in accessible regions 
(near the edge of the nucleosome or within the linker DNA) (e.g. c-MYC). 
However, there is a subset of pioneer transcription factors that can engage their 
cognate sites on the nucleosome surface as they only bind one face of the DNA 
and can accommodate nucleosomal DNA curvature (e.g. Oct4, Sox2 or Klf4) 
(Guccione et al. 2006; Soufi et al. 2012; Hebbar and Archer 2003). 
The binding of activators to their target sequences triggers the recruitment of a 
variety of co-activators, including chromatin-remodelling complexes, histone-
modifying enzymes, and Mediator1. The chromatin remodelling directed by co-
activators at promoters enhances the binding of activators and makes 
nucleosomal DNA elements more accessible to both general transcription factors 
(GTFs: TBP and TFIIA, B, D, E, F and H) and Pol II. The binding of the GTFs and Pol 
II to DNA occurs in a tightly regulated sequence of events to eventually form the 
preinitiation complex (PIC). At this point, Pol II remains at the promoter, 
synthesizing short lengths of RNA until it is released and starts elongating the 
nascent mRNA.  
In order for elongation to occur, the GTF TFIIH phosphorylates RNA Pol II ‘tail’ 
(CTD or C-terminal domain) in Ser5 (Phatnani and Greenleaf 2006). The 
polymerase then disengages from the cluster of GTFs and, as it starts travelling 
into the coding region, it undergoes a second phosphorylation in Ser2 catalysed 
                                                          
1 MEDIATOR: Protein complex which allows the activator proteins to communicate 
properly with RNA polymerase II and the general transcription factors. 
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by the TAK/P-TEFb/CDK9 complex (Marshall et al. 1996). These events signal the 
recruitment of the elongation machinery (factors involved in polymerization, 
mRNA processing, and export) and couple them with alterations in chromatin 
function. One example is PAF, an elongation factor associated with Ser5-
phosphorylated CTD that controls the binding of chromatin regulators, such as 
the H3K4 methyltransferase Set1, the histone ubiquitin ligase Rad6 or the 
chromatin-remodelling factor CHD1 (Li et al. 2007). 
 
2. c-MYC 
MYC genes are key modulators of cell proliferation and their deregulation 
contributes to almost every aspect of tumor cell biology (Adhikary and Eilers 
2005). In mammals, the main MYC family constituents are c-MYC, N-MYC, and L-
MYC, and they all share significant similarity in their genomic, RNA, and protein 
sequences. c-MYC was the first to be discovered as the cellular homolog of the 
transforming gene of the avian myelocytomatosis virus (Vennstrom et al. 1982). 
Despite the enormous progress done during these past 30 years of research, 
many aspects of c-MYC biology remain elusive (Wolf  et al. 2014). 
 
2.1. Protein structure and interaction partners 
The gene coding for c-MYC is located on the human chromosome 8q24 and is 
comprised of three exons. The predominant product is c-MYC (also known as 
p64); however, alternative translational initiation gives rise to two additional 
naturally-occurring translation products: p67 and S-MYC (Hann et al. 1984; 
Sugiyama et al. 1989). A distinct function for p67 is not known, but the shorter S-
MYC appears to play a role in stress response and might act as a dominant-
negative MYC (Spotts et al. 1997). 
The N-terminus of c-MYC contains an unstructured transactivation domain 
(TAD) which spans two highly conserved sequences known as MYC boxes (MBI 
and MBII). The TAD domain is followed by MYC boxes III and IV and a nuclear 
localization signal (Sarid et al. 1987; Fladvad et al. 2005; Cowling et al. 2006). MYC 
boxes participate in protein-protein interactions with E3 ubiquitin ligases that 
regulate c-MYC protein stability (FBW7 and SKP2) (Yada et al. 2004, Kim et al. 
2003), together with co-factors that modulate its transcriptional activity. The 
latter include histone acetyltransferases or HATs (GCN5/PCAF, TIP60, and 
CBP/p300), the histone exchange factor p400, and components of the basal 
transcriptional machinery such as Mediator and P-TEFb (McMahon et al. 2000; 
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Frank et al. 2003; Kanazawa et al. 2003; Faiola et al. 2005; Martinato et al. 2008; 
Liu et al. 2008a). Two residues within the N-terminal domain of c-MYC control its 
stability: Ser62 (S62) and Thr58 (T58). Phosphorylation of S62 by mitogen-
activated kinases stabilizes the protein, whereas phosphorylation of T58 by GSK3 
(Glycogen Synthase Kinase-3) marks it for proteosomal degradation (Sears et al. 
2000; Gregory et al. 2003). The C-terminus contains a basic DNA-binding domain 
tethered to a HLH-LZ motif involved in the dimerization with MAX (Blackwood 
and Eisenman 1991). In addition to its classical chromatin-recruitment role, the 
C-terminal domain of c-MYC is also involved in transactivation through the 
recruitment of the H3K27 acetyltransferase CBP/p300 and the nucleosome 
remodeler SWI/SNF (Cheng et al. 1999; Park et al. 2002; Vervoorts et al. 2003) 
(Fig. 2). 
 
Figure 2. Structural organization of c-MYC and interaction partners. Two key 
phosphorylation sites are indicated at Thr58 and Ser62. MB, conserved MYC boxes; TAD, 
transactivation domain; NLS, nuclear localization sequence; b, basic region; HLH, helix-
loop-helix; Zip, leucine zipper region; Med, Mediator. Adapted from Lüscher and 
Vervoorts 2012 and Adhikary and Eilers 2005. 
 
2.2. c-MYC control of gene transcription 
c-MYC mainly operates as a transcription factor that either activates or 
represses gene expression, although some non-transcriptional roles have been 
attributed to it as well (Dominguez-Sola et al. 2007; Cowling and Cole 2007). 
Transcriptional activation occurs through dimerization with MAX and binding to 
the consensus DNA sequence CACGTG (E-box). Of note, c-MYC binding to non-
canonical E-boxes and non-E-box targets has also been reported (Blackwell et al. 
1993; Zeller et al. 2006; Guccione et al. 2006).  
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The interaction with MAX is required for many of c-MYC biological functions, 
although c-MYC appears to function in the absence of a functional MAX protein 
in PC12 cells and in Drosophila (Hopewell et al. 1995; Steiger et al. 2008). 
MAX also binds bHLH-LZ-containing proteins of the MAD family and the resulting 
dimers recognize the same consensus E-boxes as c-MYC:MAX. MAD proteins 
antagonize c-MYC function by competing with c-MYC proteins for free MAX, 
competing with c-MYC:MAX dimers for available binding sites, and recruiting 
repressor complexes such as SIN3 and its associated factors N-COR and HDAC1 at 
bound sites (Alland et al. 1997). In contrast to MAX, which is ubiquitously 
expressed, MAD proteins levels are tightly regulated and restrict c-MYC’s 
functional access to DNA. 
2.2.1. Widespread binding to chromatin 
Numerous studies based on chromatin immunoprecipitation (ChIP) have shown 
that c-MYC associates with a large fraction of cellular genes in a variety of cell 
types (Schuhmacher et al. 2001; O’Connell et al. 2003; Fernandez et al. 2003; Li 
et al. 2005). These c-MYC target signatures show little overlap (Chandriani et al. 
2009). The small set of genes common to all c-MYC signatures is involved in 
processes directed towards biomass accumulation or cell growth (ribosome 
biogenesis, protein synthesis, and mitochondrial function) (Ji et al. 2011). Not 
only c-MYC modulates hundreds of genes, but it also controls genes transcribed 
by all three RNA polymerases. Thus, besides protein-coding genes and non-coding 
RNAs controlled by Pol II, c-MYC regulates rRNAs and tRNAs transcribed by Pol I 
and Pol III, respectively (Arabi et al. 2005; Gomez-Roman et al. 2003).  
When expressed at low physiological levels, c-MYC tends to occupy canonical E-
boxes within CpG-rich promoters (CpG islands). These chromatin domains are 
H3K4-methylated and constitute high-affinity binding sites common to different 
cell lines (Fernandez et al. 2003; Guccione et al. 2006). c-MYC overexpression 
results in binding to low-affinity non-canonical E-boxes situated at active 
regulatory elements in a process termed ‘invasion’ (Fernandez et al. 2003; Lin et 
al. 2012; Sabò et al. 2014). 
Genome-wide mapping of c-MYC-binding sites and associated gene expression 
studies established that c-MYC is required but not sufficient to drive gene 
transcription. c-MYC cooperates with other sequence-specific regulators to 
activate the transcription of its targets, such as E2F (Zeller et al. 2006), estrogen 
receptor  (ER) (Cheng et al. 2006) and the stem cell factors Sox2, Oct4, and Klf4 
(Kim et al. 2010). 
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2.2.2. Transcriptional activation  
c-MYC sequence-specific DNA binding is restricted by epigenetic mechanisms. 
In particular, c-MYC target sites are preferentially found within euchromatic 
islands of transcriptionally active genes: chromatin domains enriched in CpG 
islands and activating histone marks (H3K4me3, H3K79me2, and H2A.Z) 
(Guccione et al. 2006; Lin et al. 2012). The observation that c-MYC binding does 
not alter H3K4me3 levels, together with the fact that half c-MYC binding loci do 
not contain any E-box, suggests that an active chromatin configuration acts 
upstream and is a better determinant of c-MYC binding than DNA sequence 
(Martinato et al. 2008; Fernandez et al. 2003; Guccione et al. 2006).  
Once bound to its target promoters, c-MYC recruits multiple cofactors that 
introduce additional changes in the chromatin, resulting in higher DNA 
accessibility and transcriptional activation (Fig. 3). Among these cofactors are 
complexes with histone acetyltransferase activity, such as PCAF, TIP60, 
p300/CBP, and the GCN5-containing complexes TFTC and STAGA (Frank et al. 
2003; Bedford et al. 2010; McMahon et al. 2000; Nagy and Tora 2007). Histone 
hyper-acetylation reduces the ionic interactions of the positively charged histone 
tails with the negatively charged DNA backbone, thus increasing DNA 
accessibility. Additionally, histone acetylation promotes the assembly of higher-
order transcriptional complexes by recruiting proteins with acetyl-lysine-binding 
modules or bromodomains. One example is BRD4, a member of the BET subfamily 
of human bromodomain proteins that associates with acetylated chromatin and 
facilitates transcription via direct interaction with P-TEFb and Mediator (Dey et 
al. 2009; Dawson et al. 2011). c-MYC further modulates DNA accessibility through 
the recruitment of the chromatin-remodelling complex SWI/SNF. This complex 
catalyzes ATP-dependent nucleosome eviction and plays an essential role in 
transcription (Cheng et al. 1999). Interestingly, several lines of evidence suggest 
that the SWI/SNF complex and HATs act synergistically to establish a local 
chromatin structure that is permissive for subsequent events (Fry and Peterson 
2001). c-MYC also promotes the incorporation of H2A.Z at target promoters, a 
histone variant associated with transcriptionally active genes (Martinato et al. 
2008).  
In addition to increasing promoter accessibility, c-MYC regulates transcription 
by controlling RNA Pol II activity and mRNA processing. c-MYC recruits P-TEFb and 
TFIIH to target genes, which phosphorylate RNA Pol II C-terminal domain (CTD) 
and favour the release of promoter-paused Pol II (Rahl et al. 2010; Cowling and 




interacts directly with two subunits of P-TEFb: CDK9 and cyclin T1 (Eberhardy and 
Farnham 2001). Secondly, c-MYC induces histone hyper-acetylation at target 
chromatin, thus promoting BRD4:P-TEFb recruitment. Phosphorylation of Pol II 
Figure 3. Model of c-MYC transactivation. A series of steps are summarized that 
provide a model how c-MYC regulates target genes in conjunction with 
acetyltransferases, chromatin remodelers and Pol II pause release factors. Adapted 
from Lüscher and Vervoorts 2012. 
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also triggers the recruitment of mRNA capping and splicing factors, which are 
essential for the processing of the emerging transcript (Cowling and Cole 2010). 
In summary, c-MYC drives transcription by recruiting multiple co-factors to 
promoters in a pre-existing transcriptionally active or poised state and further 
modulating their activity.  
It has been suggested that c-MYC does not have a unique transcriptional 
program but, instead, it targets all active promoters and enhancers in the genome 
and acts as a non-specific general amplifier of transcription (Lin et al. 2012; Nie 
et al. 2012). Conversely, two recent reports offered an alternative to the amplifier 
model, showing that c-MYC can actually activate and repress discrete gene sets. 
The authors hypothesized that RNA amplification and promoter/enhancer 
occupancy by c-MYC are in fact separable events. The increase in global RNA 
production would be an indirect effect, explained by the nature of the targets 
regulated by c-MYC (e.g. proteins involved in nucleotide synthesis) (Sabò et al. 
2014; Walz et al. 2014; Dang 2014).  
2.2.3. Transcriptional repression  
Ectopic expression of c-MYC leads to down-regulation of specific genes 
encoding negative regulators of cell proliferation (e.g. Cdkn2b, Cdkn2c or Cdkn1a) 
and proteins involved in cell adhesion (Itgb1) and cell-cell communication. c-MYC 
represses transcription by binding to the core promoter of target genes. Some 
original studies suggested that this process occurred independently of c-MYC 
binding to DNA. However, c-MYC recruitment to Cdkn2b requires dimerization 
with MAX, and E-box elements have been found in the core promoter of genes 
repressed by c-MYC (Herkert and Eilers 2010). 
Mechanistically, c-MYC represses transcription by binding to two transcription 
factors: MIZ1 and SP1 (Peukert et al. 1997; Gartel et al. 2001). The interaction 
with c-MYC results in the displacement of the co-factors CBP/p300 and 
nucleophosmin (NPM), and recruitment of repressors such as the histone 
deacetylase HDAC3 and the DNA methyltransferase DNMT3A (Staller et al. 2001; 
Brenner et al. 2005; Kurland and Tansey 2008; Wanzel et al. 2008). c-MYC also 
modulates MIZ1 through the induction of RPL23, a ribosomal protein that 
sequesters NPM to the nucleolus and thus hampers MIZ1 activity (Wanzel et al. 
2008). The case of TGF-mediated cell cycle arrest illustrates the MYC-MIZ1 
interaction. In the absence of TGF signalling, c-MYC represses Cdkn2b (p15INK4B) 
in a complex with MIZ1. Increased levels of TGF lead to phosphorylation and 
nuclear translocation of SMAD proteins, which cooperate with MIZ1 in inducing 
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Cdkn2b expression. In parallel, activated SMADs inhibit c-Myc transcription 
(Seoane et al. 2001).  
2.3. c-MYC biological roles 
c-MYC is almost universally present in proliferating normal somatic cells, where 
it operates as an integrator of extracellular stimuli transduced by multiple 
signaling cascades (e.g. Wnt, Ras/Raf/MAPK, JAK/STAT or TGFb). As a result, it 
modulates a wide range of cellular processes such as proliferation, growth, 
apoptosis, metabolism, and differentiation. In normal cells, c-MYC is under tight 
transcriptional and post-transcriptional control, and its expression is continuously 
dependent upon mitogenic signalling.  
By contrast, cancer cells typically show a deregulated and elevated c-MYC 
expression, which is responsible for changes in chromatin structure, ribosome 
biogenesis, metabolic pathways, cell, and angiogenesis among others (Lin et al. 
2012) (Fig. 4).  
2.3.1. Cell proliferation and differentiation 
c-MYC has a crucial role in cell division by controlling the transition from G0/G1 
to S phase. It regulates proliferation by transcriptionally activating genes involved 
in cell cycle progression (e.g. cyclin D1, cyclin D2 or CDK4) and repressing 
checkpoint genes and cyclin-dependent kinase inhibitors (e.g. GADD45, p15INK4B 
or p21CIP1). Moreover, c-MYC enhances DNA replication by binding to pre-
replicative complexes and promoting origin firing (Dominguez-Sola et al. 2007). 
c-MYC overexpression and/or deregulation is associated with unscheduled firing 
of DNA replication origins, DNA damage response, and checkpoint activation 
(Murga et al. 2011).  
Several experiments document the ability of c-MYC to inhibit differentiation of 
various cell types in vitro (e.g. murine ES cells) and in vivo (e.g. B cell lymphomas) 
(Cartwright et al. 2005; Langdon et al. 1986). However, c-MYC role is far more 
complex. In tissues where commitment to a specific lineage is linked to an 
increase in proliferation, c-MYC promotes cell differentiation by controlling the 
exit from the stem cell niche. One example is the skin, where ectopic expression 
of c-MYC is associated with the depletion of the stem cell compartment and an 
accumulation of differentiated layers (Waikel et al. 2001). Part of c-MYC role in 
driving differentiation of keratinocytes involves its ability to reduce adhesive 





Figure 4. Schematic representation of the cellular functions mediated by c-MYC 
under physiological and oncogenic (red shapes) situations. c-MYC can influence 
transcription of protein-coding genes, as well as noncoding rRNAs and miRNAs. c-
MYC can also stimulate DNA replication and chromatin remodelling by non-
transcriptional functions. Deregulation of c-MYC activity at any of these levels can 




2.3.2. Cell growth and metabolism 
c-MYC promotes cell growth by providing the cell with an abundant supply of 
basic building blocks as well as increasing cell metabolism and protein synthesis. 
Several c-MYC target genes participate in this activity, including those associated 
with metabolism, ribosomal and mitochondrial biogenesis, and protein and 
nucleic acid synthesis. 
2.3.3. Apoptosis 
Ectopic expression of c-MYC in the presence of limiting survival signals or cell 
stress sensitizes cells to undergo apoptosis. This phenomenon has been reported 
in both cells and transgenic mice in which c-MYC is expressed under the control 
of a foreign promoter (Evan et al. 1992; Jacobsen et al. 1994). c-MYC-induced 
apoptosis is an example of intrinsic tumor suppression, a defence mechanism 
against the tumorigenic potential of oncogenes. In fact, suppression of c-MYC 
pro-apoptotic activity is essential to tumorigenesis. Noticeably, it is 
overexpression, rather than deregulation, what is required in order for c-MYC to 
trigger apoptosis (Murphy et al. 2008).  
Several mechanisms are involved in c-MYC-mediated apoptosis. High c-MYC 
levels upregulate p19ARF, an inhibitor of the MDM2 E3 ligase, which leads to the 
stabilization of p53 (Zindy et al. 1998). p53 regulates a cohort of target genes 
involved in apoptosis and growth arrest. FoxO transcription factors have been 
shown to mediate c-MYC-induced p19ARF expression through direct binding to the 
Ink4a/Arf locus (Bouchard et al. 2007). 
c-MYC can also trigger apoptosis by altering the balance between pro- and anti-
apoptotic factors, in parallel with or independent of p53. c-MYC indirectly 
suppresses the anti-apoptotic proteins BCL2 and BCL-XL and induces the pro-
apoptotic Bax and BIM (Strasser et al. 1990; Eischen et al. 2001; Mitchel et al. 
2000; Egle et al. 2004). These events lead to the release of cytochrome c from the 
mitochondria and the subsequent activation of downstream effector caspases.  
Moreover, c-MYC overexpression activates apoptosis through the induction of 
DNA instability and breaks. This appears to be the consequence of several 
mechanisms: inhibition of double-stranded DNA repair and/or increase in 
reactive oxygen species (Vafa et al. 2002; Karlsson et al. 2003). 
2.3.4. Tumorigenesis 
c-MYC is over-expressed and/or deregulated in more than half of human cancers 
(Gabay et al. 2014); high levels being associated with aggressive, poorly 
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differentiated tumors. This occurs through multiple mechanisms, including 
amplification, chromosomal translocation, single nucleotide polymorphisms in 
regulatory regions, constitutive activation of upstream signalling pathways and 
mutations that enhance c-MYC protein stability (Eilers and Eisenman 2008; Meyer 
and Penn 2008).  
Even though c-MYC is one of the most potent oncogenes, its sole activation in 
normal cells is not able to induce neoplastic transformation. Moreover, tumors 
that arise from c-MYC transgenic mice are clonal, suggesting that additional 
mutations are required for tumor formation. c-MYC-induced cell transformation 
is restrained by two mechanisms. First, c-MYC half-life and function are 
modulated by Ras-dependent signalling pathways. Second, several mechanisms 
exist that protect cells from unchecked cell growth: proliferative arrest, 
senescence, and/or apoptosis. Therefore, Ras activating mutations and genetic 
events that abrogate these checkpoints (e.g. p53 loss) often synergize with c-MYC 
to induce tumors (Adhikary and Eilers 2005). 
When pathologically activated in a permissive context, c-MYC enforces many of 
the "hallmark" features of cancer, including relentless DNA replication, cellular 
proliferation and growth, protein synthesis, and altered metabolism. c-MYC 
mandates tumor cell fate by inducing stemness and blocking cellular senescence 
and differentiation. Additionally, c-MYC orchestrates changes in the tumor 
microenvironment, including the activation of angiogenesis and suppression of 
the host immune response (Gabay et al. 2014).  
c-MYC plays a role both in tumor initiation and maintenance. In transgenic 
mouse models with inducible c-MYC, established tumors regress upon 
withdrawal of c-MYC ectopic expression (e.g. hematopoietic, epithelial, and 
mesenchymal tumors) (Arvanitis and Felsher 2006). Interestingly, brief 
suppression of c-MYC using the inducible dominant negative ‘Omomyc’ can result 
in restoration of checkpoint mechanisms, resulting in tumor regression, 
remodelling of the tumor microenvironment, and shutdown of angiogenesis. 
Therefore, tumors appear to be “addicted” to c-MYC (Soucek et al. 2002; Soucek 
et al. 2008).  
Cellular transformation by c-MYC depends on specific cell cycle and metabolic 
pathways. For example, c-MYC enhances glucose uptake and glycolysis through 
transcriptional activation of different target genes, including lactate 
dehydrogenase A (LDHA). Induction of LDHA might explain the “Warburg effect”; 
namely, the observation that tumor cells show enhanced rates of glycolysis even 
under aerobic conditions (Shim et al. 1997). 
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Several transgenic mouse models have been developed to elucidate the 
mechanism whereby deregulated c-MYC contributes to tumorigenesis (Table 2). 
 
Table 2. Representative mouse models used to study c-MYC function. Adapted from 
Meyer and Penn 2008. 
2.3.5. Reprogramming 
While not absolutely required, ectopic expression of c-MYC augments the 
efficiency and kinetics of formation of pluripotent cells from mouse and human 
fibroblasts and mature B cells (Nakagawa et al. 2008; Takahashi et al. 2007; 
Hanna et al. 2008). c-MYC facilitates the initial steps of the reprogramming 
process, both repressing fibroblast-specific genes and enhancing the binding of 
OSK (Oct4, Sox2 and Klf4) to chromatin (Soufi et al. 2012; Sridharan et al. 2009). 
In addition, c-MYC fulfils other functions such as regulating DNA replication and 




Chromatin constitutes a barrier for the interaction of trans-acting factors with 
DNA and thus regulates processes such as transcription, DNA replication, DNA 
repair, and recombination. Epigenetic mechanisms that regulate DNA 
accessibility include post-translational modifications of histones, DNA 
methylation, incorporation of histone variants, and nucleosome remodelling 
activities. The latter two are mainly orchestrated by ATP-dependent chromatin 
remodelling complexes. These complexes are in turn grouped in 4 sub-families 
based on the sequence homology of the associated ATPase: SWI/SNF, ISWI, CHD, 
and INO80.  
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BPTF (Bromodomain PHD Transcription Factor) is the mammalian orthologue of 
Drosophila Nurf301 and constitutes the largest and essential subunit of the ISWI 
complex NURF (Nucleosome Remodelling Factor). NURF is an ATP-dependent 
chromatin remodeller that catalyses nucleosome sliding without eviction or 
exchange of histones from the nucleosome. Mammalian NURF consists of BPTF, 
SNF2L (an ISWI ATPase), and RbAp46/48, a histone-binding protein found in 
several chromatin-related complexes (Jones et al. 2000; Hamiche et al. 1999; 
Barak et al. 2003). BPTF provides sequence specificity to NURF through 
interactions with transcription factors and histone modifications (Xiao et al. 2001; 
Alkhatib et al. 2011). 
 
3.1. Protein structure and interactors 
The BPTF gene maps to the 17q24.3 locus and codes for two protein products: 
BPTF (2871 aa) and its C-terminal truncated version FALZ (Fetal Alzheimer Antigen 
or FAC1). While BPTF is ubiquitously expressed in adult tissues, FALZ is restricted 
to the brain neocortex. It was proposed that FAC1 acts as a transcriptional 
regulator through binding to a consensus DNA sequence present in genes 
implicated in neurodegenerative disorders (e.g. PSEN1 or DRD2) (Jordan-Sciutto 
et al. 1999a). 
The functional domains within BPTF are consistent with a role for this protein in 
chromatin-mediated regulation of transcription. The N-terminus of BPTF contains 
a HMGA domain or acidic patch, a DDT DNA-binding domain, and a PHD domain. 
The C-terminal domain of BPTF includes a glutamine-rich region which is 
intrinsically disordered, a second PHD domain, and a bromodomain. The latter 
two constitute a histone recognition module that binds H3K4me2/3 and 
H4K16ac, respectively (Doerks et al. 2001; Wysocka et al. 2006; Ruthenburg et al. 
2011). Additional features include nuclear localization signals, proline-rich 
regions, and LXXLL motifs that could be important for the interaction with nuclear 
receptors (Savkur and Burris 2004). 
Human BPTF preferentially associates with H2A.Z, a histone variant 
incorporated at promoter and regulatory regions whose deposition correlates 
with gene expression (Marques et al. 2010). Moreover, the ATPase SNF2L 






3.2. Biological function of BPTF 
3.2.1. Transcriptional activator and repressor 
Chromatin remodelling machines have been traditionally thought to be required 
exclusively during gene activation to expose or “open-up” chromatin. In 
agreement with this view, NURF has been shown to facilitate transcription of 
chromatin in vitro and in vivo. This effect is not observed with naked DNA 
templates, suggesting that it functions to relieve the inhibitory effects of 
chromatin on transcription (Mizuguchi et al. 1997; Badenhorst et al. 2002). 
However, several lines of evidence indicate that NURF can also repress gene 
transcription (Goldmark et al. 2000; Badenhorst et al. 2002; Landry et al. 2008).  
Many studies have shown interactions between BPTF/Nurf301 and both 
ubiquitous (AP-1, SRF or Usf1) and cell-type-restricted (PR and Smad) 
transcription factors (Table 3). As a result, BPTF regulates the expression of a 
largely non-overlapping set of genes between cell types (Qiu et al. 2015). This 
stands in contrast to members of the SWI/SNF family, which have more global 
roles in regulating gene expression through interactions with RNA polymerase 
(Armstrong et al. 2002). 
 
Table 3. Summary of published NURF interactions with transcription factors. Adapted 




3.2.2. Chromatin structure 
In addition to having key roles in transcription, NURF is a general regulator of 
chromatin structure.  
Inactivation of Drosophila Nurf301 leads to dramatic decondensation of the 
male X chromosome (Badenhorst et al. 2002). NURF effects on X chromosome 
chromatin architecture could be direct, through nucleosome remodelling, or 
indirect, through the transcriptional regulation of genes involved in this process. 
One possible mechanism would be through NURF-dependent localization of the 
ATAC acetyltransferase (Carré et al. 2008).  
NURF has also been characterized as a regulator of insulator elements in a 
number of contexts. Drosophila NURF has been proposed to be recruited to 
insulators by the GAGA factor, where it repositions nucleosomes to facilitate 
insulator function (Xiao et al. 2001; Li et al. 2010). Similarly, human NURF is 
critical for the barrier function of the USF-bound insulator 5’HS4, which prevents 
erythroid genes from encroachment by heterochromatin (Li et al. 2011). 
Interestingly, a recent report identified BPTF as a facilitator of the 
interchromosomal interactions that take place between the enhancers of 
olfactory receptor genes. These long-range interactions account for the 
robustness of olfactory gene expression (Markenscoff-Papadimitriou et al. 2014). 
Overall, these data suggest that BPTF:NURF modulates gene expression directly, 
through the interaction with transcription factors, and indirectly, through the 
regulation of high-order chromatin structures. 
3.2.3. Developmental regulator 
NURF has been shown to be essential for specific stages of metazoan 
development, functioning in pathways signalling to the nucleus, including heat 
shock, TGF/Smad, JAK/STAT, WNT/-catenin, and nuclear hormone receptors. 
D. melanogaster: Nurf301 is required to maintain homeotic gene expression 
during development, represses JAK/STAT signalling in the immune system, and 
promotes ecdysone signalling during metamorphosis (Xiao et al. 2001; 
Badenhorst et al. 2002; Badenhorst et al. 2005; Kwon et al. 2008). It also plays a 
role in the development of larval blood cells and in the maintenance of the germ 
stem cells compartment in Drosophila testis (Badenhorst et al. 2002; Cherry and 
Matunis 2010).  
M. musculus: Bptf knockout mice do not gastrulate due to defects in the 
differentiation of extra-embryonic tissue lineages: the distal visceral endoderm 
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and the ectoplacental cone (Goller et al. 2008; Landry et al. 2008). For this reason, 
the characterization of NURF function in the adult mammal has been limited. Cre-
LoxP conditional knockout technology revealed that BPTF is essential for adult 
thymocyte development (Landry et al. 2011). 
H. sapiens: In a competitive epidermal reconstitution assay, BPTF was identified 
as a negative regulator of epidermal differentiation (Mulder et al. 2012). 
 
3.3. BPTF in human cancer 
Several lines of evidence suggest that BPTF could play a tumor-promoting role 
in human cancer. Firstly, primary human cancers and cancer cell lines frequently 
duplicate the 17q chromosome arm containing the BPTF gene. In fact, partial gain 
of 17q is the most abundant genetic alteration in neuroblastoma (Bown et al. 
1999; Alkhatib et al. 2011). Secondly, mutations targeting BPTF have been 
reported for several human tumors (e.g. lung, breast, bladder, liver, and uterine 
cancer) (Xiao et al. 2014a; Balbás-Martínez et al. 2013; Fujimoto et al. 2012; 
González-Pérez et al. 2013). Finally, BPTF was appointed in a recent report as an 
independent marker for survival prediction in hepatocellular carcinoma patients; 
high BPTF levels being associated with invasiveness, recurrence, and poor 










The specific aims for this thesis were: 
1. To investigate the role of BPTF in normal mammalian cells by analyzing the 
effect of its inactivation in both cell lines and mouse tissues. 
2. To assess the function of BPTF in c-MYC transcriptional activity using a 
combination of biochemical assays and genome-wide approaches. 
3. To study the role of BPTF in c-MYC biological activity using cell cultures 
expressing a tamoxifen-inducible form of c-MYC. 
4. To determine the relevance of BPTF in tumorigenesis by analyzing publicly 
available genomic data on human tumors and also by studying the impact of 










Los objetivos específicos de esta tesis fueron: 
1. Investigar la función de BPTF en células normales de mamífero por medio del 
análisis de los efectos de su inactivación en líneas celulares y tejidos de ratón. 
2. Evaluar el papel de BPTF en la actividad transcripcional de c-MYC usando una 
combinación de ensayos bioquímicos y aproximaciones genómicas globales. 
3. Estudiar el papel de BPTF en la actividad biológica de c-MYC usando cultivos 
celulares que expresan una forma de c-MYC inducible por tamoxifeno. 
4. Determinar la relevancia de BPTF en cáncer por medio del análisis de datos 
genómicos públicos de tumores humanos así como del estudio del impacto de 
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MATERIALS AND METHODS 
1. CELL CULTURE 
1.1. Cell lines and reagents  
Primary neonatal human foreskin fibroblasts (HFF), 293T (transformed human 
embryonic kidney cells), and human cancer cells - MIA PaCa-2, PK9 (pancreas) and 
VM-CUB-3 (bladder) - were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Sigma-Aldrich, St Louis, MO, USA) supplemented with 10% Foetal Bovine 
Serum (FBS; HyClone, Logan, UT, USA), sodium pyruvate (Life Technologies, 
Madrid, Spain), and penicillin/streptomycin (Life Technologies). Mouse Bptf+/+ 
and Bptflox/lox MEFs (Murine Embryonic Fibroblasts) were cultured in DMEM 
supplemented with 10% FBS, sodium pyruvate, non-essential amino acids (Life 
Technologies), -mercaptoethanol (Sigma-Aldrich), and penicillin/streptomycin. 
NAMALWA and RAJI Burkitt lymphoma cells were cultured in suspension in RPMI 
medium (Sigma-Aldrich) supplemented with 10% FBS and penicillin/ 
streptomycin. 
MEFs were generated by mechanical disruption and trypsin-digestion of E13.5 
embryos from which the foetal liver and the head had been removed. 
Recombination efficiency of exon 2 upon Cre recombinase expression was 
evaluated by PCR on genomic DNA as reported elsewhere (Landry et al. 2008). 
The following primers were used: CTCAGGAATTAAGAGGTAATTGACTATC, 
TGATTTAGTTCTGATTGTTAGGTCTAC, and AGACCAGCCTGTTCTACATGGCCAGCC. 
Additionally, recombination efficiency was assessed by RT-qPCR using the 
following primers:  
Amplified region  Sequence Species 
Exon1-Exon2 
Junction 
Forward AAGCAGCTTCAGGAGCCATA Mouse 
Reverse AGCAAAAAGGGGACAACCT Mouse 
Exon1-Exon3 
Junction 
Forward CAGCAGCACTCCAGAGAAGA Mouse 
Reverse CGCTAGGAAGGACTTGTTGC Mouse 
Exon1-Exon4 
Junction 
Forward CAGCAGCACTCCAGAGGAAA Mouse 
Reverse GCTCTTCTCAGCATCCTTGG Mouse 
 
1.2. Plasmids, viral constructs and virus production 
Mission shRNAs (Sigma-Aldrich) were used to carry out RNA-interference 
experiments. Out of 3 BPTF-targeting shRNAs, two were selected because they 
provided optimal knockdown (shBPTF-1, clone TRCN0000016819; shBPTF-2, 
clone TRCN0000016820) and compared to a control non-targeting shRNA. MYC-
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ER was expressed from the cDNA cloned into the FG12 plasmid by V.J. Sánchez-
Arévalo (CNIO, Madrid). For lentiviral transduction of Cre recombinase, we used 
the lentiviral vector pLVXpuro-iCRE-ORF, a gift from C. Bar and M.A. Blasco (CNIO, 
Madrid). The packaging plasmid pCL-Eco and the retroviral constructs expressing 
pluripotency factors were generously provided by C.J. Lynch and M. Serrano 
(CNIO, Madrid). 
Lentiviral production: Infectious lentiviruses were produced in 293T cells by 
calcium phosphate-mediated transfection of the lentiviral construct together 
with the packaging plasmids psPAX2 and pCMV-VSV-G. Post-transfection (48h), 
the medium was harvested twice for an additional 48h. Viral supernatants were 
filtered and either frozen down in aliquots or applied on target cells in the 
presence of 5 µg/ml polybrene. Cells were used after 48h puromycin selection (2 
μg/ml). Human fibroblasts were infected first with lentivirus coding for MYC-ER, 
expanded, and then infected with either control or BPTF-targeting shRNAs. MEFs 
were infected concomitantly with lentivirus encoding for MYC-ER and Cre 
recombinase. 
Retroviral production for reprogramming of MEFs into iPSc: Retroviral 
supernatants were produced in HEK-293T cells (5×106 cells per 100-mm-diameter 
dish) transfected with the packaging plasmid pCL-Eco (4 μg) together with one of 
the following retroviral constructs (4 μg): pMXs-Klf4, pMXs-Sox2, pMXs-Oct4 or 
pMXs-cMyc. Transfections were performed using Fugene-6 transfection reagent 
(Roche, Basel, Switzerland) according to the manufacturer’s protocol. Two days 
post-transfection, retroviral supernatants were collected at 12 h intervals, each 
time adding fresh medium to the cells. 
Infection of BL cell lines: BL cells (3×105 cells/well) were seeded on plastic plates 
coated with retronectin (Fisher Scientific, Pittsburgh, PA, USA) and preloaded 
with viral supernatants. After 3 additional rounds of infection with viral 
supernatants supplemented with polybrene (8 μg/ml), cells were allowed to 
recover for 24h, then selected for 48h in puromycin-containing medium (2 
g/ml). After selection, cells (sh#1, sh#2 and shNT) were plated (5x103/well in 96-
well plates) in replicates. Viable cell count was assessed at the indicated time 
points by adding WST1 cell proliferation reagent (Roche) to each well and 
determining OD450 nm after 2 h, according to the manufacturer's instructions. 
1.3. iPS Reprogramming 
Early passage (2-3) primary MEFs were reprogrammed following a protocol 
described elsewhere (Li et al. 2009). Recipient MEFs were seeded the previous 
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day (150,000 cells on a 6-well plate) and received 1.5 ml of each of the 
corresponding retroviral supernatants (3F: 4.5 ml in total; 4F: 6 ml in total). This 
procedure was repeated 4 times in total. At 48 h after the ﬁrst round of infection, 
medium was changed to iPSC medium (DMEM high glucose supplemented with 
serum replacement (KSR, 15%, Invitrogen), leukemia inhibitory factor (LIF) (1000 
U/ml), non-essential amino acids, glutamax and -mercaptoethanol). Cultures 
were maintained in the absence of drug selection with daily medium changes. At 
day 12-14, colonies with ES-like morphology were scored after staining for AP 
activity (BCIP/NBT Colour Development Substrate, Promega, S3771). Colonies 
were picked at day 14 and expanded on feeder fibroblasts using standard 
procedures. 
1.4. FACS analysis of proliferation and apoptosis 
For proliferation assays of MEFs, cells were pulse-labelled with 10 M BrdU 
(Sigma-Aldrich) for 1 h, harvested by trypsinization and then fixed in 100% 
ethanol. Upon DNA denaturation using 2 N HCl, cells were stained with mouse 
anti-BrdU primary antibody (Santa Cruz Biotechnology, sc-51514; 1g/106 cells) 
and anti-mouse Alexa Fluor 488-conjugated secondary antibody (Life 
Technologies, A21202; 1g/106 cells). DNA was stained by resuspension of cells 
in 0.1 mg/ml propidium iodide and incubated 30 min at room temperature until 
FACS analysis.  
In order to measure apoptosis, MEFs were seeded at high density and then 
transferred to 0.5% FBS-containing DMEM in the presence of either vehicle 
(EtOH) or 2 mM 4-OHT. At the indicated time points, cells and supernatants were 
harvested, washed, and resuspended in Annexin V binding buffer containing 5 l 
per sample of Annexin V-APC (BD Biosciences, 550474, Franklin Lakes, NJ, USA). 
Prior to analysis, DAPI was added.  
 
2. MOUSE BIOLOGY 
2.1. Mouse strains 
The following mouse strains were used: Bptflox/lox (Landry et al. 2008), Ptf1a-
Cre+/KI (Kawaguchi et al. 2002), Ptf1a-CreERT2+/KI (Kopinke et al. 2011), Ela1-Myc 
(Sandgren et al. 1991), Mb1-Cre+/KI (Hobeika et al. 2006) and E-Myc (Harris et al. 
1988). Mb1-Cre mice were provided by Dr. A.M. Ramiro (CNIC, Madrid), and E-
Myc mice were supplied by Dr. C. Blanco (CNIO, Madrid). C57BL/6 Bptflox/lox mice 
were obtained from Jackson Laboratories (stock number 009367). Other strains 
were available at CNIO. 
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To determine the role of BPTF in c-MYC-driven pancreatic tumorigenesis, we 
administered 25 mg of tamoxifen (Sigma-Aldrich, T-5648) by gavage over the 
course of one week to 5-7 weeks old Bptflox/lox; Ptf1a-CreERT2+/KI; Ela1-Myc mice 
and their corresponding controls. Mice were screened for pancreatic tumors once 
a week using a small animal ultrasound system.  
Mice were housed under specific pathogen-free conditions according to 
institutional guidelines. Mice were observed on a daily basis and sacrificed when 
they showed signs of morbidity or tumor burden was greater than 10% body 
weight in accordance with the Guidelines for Human Endpoints for Animals Used 
in Biomedical Research. All experiments were approved by the ISCIII (Instituto de 
Salud Carlos III) Ethical Committee and performed in accordance with the 
guidelines for Ethical Conduct in the Care and Use of Animals as stated in The 
International Guiding Principles for Biomedical Research involving Animals, 
developed by the CIOMS. 
2.2. Histopathology and Immunohistochemistry 
Mouse tissues were fixed in 4% PBS-buffered formaldehyde, embedded in 
paraffin and serially sectioned. 4 m sections were deparaffinized and stained 
with hematoxylin-eosin or specific antibodies. 
For immunohistochemistry, mouse tissue sections were prepared as follows. 
After deparaffinization, sections were rehydrated and boiled in 10 mM sodium 
citrate buffer (pH 6) for 10 min to retrieve the antigens. Next, sections were 
washed in distilled water and incubated for 30 min with 3% hydrogen peroxide in 
methanol, after which they were washed again and blocked for 30 min with 2% 
BSA in PBS/0.5% Triton X-100. After blocking, the sections were incubated with 
primary antibodies in 2% BSA in PBS/0.1% Triton X-100 for 1h at room 
temperature. Antibody dilutions used: P-Histone H3 (Abcam ab14955), 1:2000; c-
Myc (Millipore 06-340), 1:300; cleaved caspase 3 (R&D AF835), 1:300. Next, 
sections were washed in PBS/0.1% Triton X-100 three times and incubated for 30 
min with Envision+ HRP-labelled secondary antibodies (Dako, Glostrup, 
Denmark). Sections were washed again and the staining was developed using 
DAB Chromogen system (Dako). Sections were rinsed with water, counterstained 
with Carazzi's Hematoxylin solution DC (Panreac, Castellar del Vallès, Spain), 
dehydrated with increasing concentrations of alcohol and xylol, and mounted 




2.3. Hematological analysis and characterization of B cell compartment  
For the analysis of cellular components of peripheral blood of Bptflox/lox; Mb1-
Cre+/KI mice, samples were collected from 8-10 week old mice and assessed using 
an Abacus Junior Hematology Analyzer. 
In order to assess the bone marrow (BM) and spleen B cell compartments, single 
cell suspensions were prepared according to standard procedures (Iritani et al. 
1997). BM cells were harvested by flushing two tibias and two femurs per mouse 
with 5 ml of RPMI 10% FBS (HyClone). Splenocytes were prepared by crushing 
spleens through 70m filters and into the above media. Next, erythrocytes were 
depleted by incubation in ammonium chloride buffer (0.15 M NH4Cl, 10 mM 
NaHCO3, 1 mM EDTA, pH 7.4) for 2 min at 37 ºC. Cells were collected by 
centrifugation for 5 min at 1,200 rpm and resuspended in 1 ml of FACS buffer (2 
mM EDTA in PBS/0.1% BSA) for further analysis. Prior to staining, cell suspensions 
were blocked for 20 min in FACS buffer supplemented with 1:200 FC block (BD 
Pharmingen, purified rat anti-mouse CD16/CD32, 553142). 3-4 colour flow 
cytometry analyses were performed by staining 4×106 cells with 0.25 g of the 
following mAbs directed against lineage markers (in various combinations): APC‐
conjugated anti‐CD45R/B220 (ebioscience, 17-0452, San Diego, CA, USA), FITC‐
conjugated anti‐CD43 (ebioscience, 11-0431-81), PE‐conjugated anti‐IgM 
(ebioscience, 12-5790-81). Samples were analyzed using a FACS Canto II (BD 
Biosciences) flow cytometer. Analyses were performed using FlowJo flow 
cytometry analysis software. 
 
3. MOLECULAR BIOLOGY  
3.1. Western blotting 
Cells were lysed in RIPA buffer supplemented with protease and phosphatase 
inhibitors. Following sonication, clearing by centrifugation, and protein 
determination, equal amounts of protein per sample were subjected to 
electrophoresis in 8% or 10% polyacrylamide SDS gels, or in NuPAGE® 3-8% Tris-
acetate precast polyacrylamide gels (Life Technologies). Samples were run under 
reducing conditions and then transferred to nitrocellulose membranes, which 
were blocked with TBST, 5% skim milk. Membranes were subsequently incubated 
with the following primary antibodies: BPTF (ab72036, Abcam, Cambridge, UK; 
1:500) and Vinculin (Sigma-Aldrich, V9131-2ML; 1:2000). This was followed by 
incubation with horseradish peroxidase-conjugated secondary antibodies (Dako). 
Reactions were detected using the ECL system. 
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3.2. Co-immunoprecipitation analyses 
For the analysis of c-MYC:BPTF interaction, the following plasmids were used: 
BPTF-Flag (courtesy of O. Barak, Wistar Institute, Philadelphia, USA) and HA-
tagged c-MYC (a gift from V.J. Sánchez-Arévalo, CNIO, Madrid).   
293T cells transiently transfected with the corresponding plasmids were washed 
twice with ice-cold PBS and lysed for 30 min on ice with NP-40 lysis buffer (150 
mM NaCl, 50 mM Tris pH 8.0, 1% NP-40) supplemented with a protease inhibitor 
cocktail. Lysates were then centrifuged at 16,000 x g for 20 min at 4 ºC. Total 
protein (1 mg) was incubated with primary antibody (2 g) overnight. Protein A/G 
agarose beads (Laboratorios Conda, Madrid, Spain) preblocked with BSA were 
then added to the lysates. Following 4 h incubation at 4 ºC, beads were washed 
3 times with NP-40 lysis buffer and immunoprecipitated proteins were eluted 
with SDS sample buffer by boiling at 90 ºC. SDS-PAGE electrophoresis was then 
performed on 6% and 10% (w/v) gels and proteins were then transferred onto 
nitrocellulose membranes.  
3.3. Generation of polyclonal anti-BPTF anti-sera 
The RLHRMTSIEREEKEKVKKKEKKQEEETC peptide was chemically synthesized, 
coupled to Keyhole limpet hemocyanin (KLH), and used as immunogen for the 
generation of polyclonal antibodies against BPTF. Two rabbits were inoculated 
subcutaneously with 500 g of peptide-KLH conjugate emulsified in Freund’s 
Complete Adjuvant (FCA). Five rounds of 250 g peptide-KLH boosters were 
administered together with Freund’s Incomplete Adjuvant (FIA) to each animal in 
the interval of three weeks. Test bleeds were taken 10 days after the last boost. 
Antibodies raised against BPTF were purified from serum by affinity 
chromatography on a HiTrap NHS-activated High Performance column (Sigma-
Aldrich, GE17-0716-01) and tested by ELISA, in HEK293T-BPTF-Flag transfected 
cells and in BPTF-silenced VM-CUB-3 cells. 
3.4. Immunofluorescence staining and Proximity Ligation Assay 
Cells grown on coverslips were fixed with 4% paraformaldehyde for 10 min, 
washed, and permeabilized with 0.1% Triton X-100 in PBS for 10 min. Samples 
were washed in PBS and blocked with 3% BSA in PBS for 1 h at room temperature. 
Primary antibody incubation was performed in blocking solution for 2 h at room 
temperature. Mouse anti-MYC (C-33, sc-42, Santa Cruz Biotechnology, Dallas, TX, 
USA) was used at a 1:50 dilution and home-made affinity-purified rabbit anti-
BPTF antibodies (residues 913-942) were used at 10 g/ml. After three washes 
with PBS, cells were incubated with an appropriate secondary antibody diluted in 
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blocking solution. Nuclei were counterstained with DAPI and coverslips were 
mounted on ProLong® (Life Technologies). Images were taken with a confocal 
microscope, using a 40X immersion oil lens. For the proximity ligation assay (PLA), 
the DuolinkII fluorescence system was used (Olink Bioscience, Uppsala, Sweden). 
3.5. Quantitative real-time PCR 
To isolate RNA from cultured cells, we used the GenElute™ Mammalian Total 
RNA Miniprep Kit (Sigma-Aldrich) according to manufacturer’s instructions. To 
isolate RNA from mouse tissue samples, we first homogenized the tissues using 
the T10 basic ultra-turrax homogenizer (IKA, Staufen, Germany) in a guanidine 
thiocyanate buffer (4 M Guanidine thiocyanate, 0.1 M Tris-HCl, 1% -
mercaptoethanol, pH 7.5 in DEPC-treated water). Total RNA was subsequently 
extracted by phenol-chloroform and isopropanol precipitation. 
All samples were treated with DNAse I before reverse transcription. cDNA was 
generated from 1 g RNA using random hexamers and Reverse Transcriptase. 
Real-time PCR amplification and analysis were conducted using the 7900HT Real-
Time PCR System (Applied Biosystems, Life Technologies). RNA levels were 
normalized to GAPDH expression using the Ct method (Livak and Schmittgen 
2001). For RT-qPCR analysis, primers were designed to achieve product lengths 





Table 4. List of RT-qPCR primers used in this study. The following primer sequences 
were a gift from B. Amati (IFOM, Milan, Italy): NCL, NOLC1 and CCND2. Primers 
targeting Nanog, Oct4 and Sox2 were designed by Takahashi et al. 2007. Primer 
sequences for murine pancreatic markers were designed by A. Pinho and former 
members of the Epithelial Carcinogenesis Group in CNIO. 
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3.6. Chromatin immunoprecipitation 
Cells were fixed with 1% formaldehyde for 15 min at room temperature. Fixation 
was stopped by adding glycine (to 0.125 M) with an additional incubation of 5 
min. Cells were harvested by scraping, pelleted, and then lysed for 10 min in 1 ml 
of buffer LB1 (140 mM NaCl, 1 mM EDTA, 50 mM Hepes pH 7.5, 0.5% NP-40, 
0.25% Triton X-100, 10% glycerol) supplemented with protease inhibitors 
(Qiagen, Valencia, CA, USA). After centrifugation at 3,000xg, pelleted nuclei were 
resuspended in 1 ml of buffer LB2 (200 mM NaCl, 0.5 mM EGTA, 1 mM EDTA, 10 
mM Tris pH 8.0), and incubated at room temperature for 10 min. Pelleted nuclei 
were resuspended in 1 ml ChIP SDS buffer (100 mM NaCl, 5 mM EDTA, 50 mM 
Tris pH 8, 0.2% NaN3, 0.5% SDS) and sonicated for 20 min in a Covaris sonicator, 
yielding DNA fragments of 300-500 bp. Beads were blocked overnight in PBS with 
0.5% BSA and then added to the samples. After a 3 h incubation  at 4 ºC, beads 
were washed with Triton dilution buffer (100 mM NaCl, 5 mM EDTA, 100 mM Tris 
pH 8.6, 0.2% NaN3, 5% Triton X-100), mixed micelle wash buffer (150 mM NaCl, 5 
mM EDTA, 5% sucrose, 20 mM Tris pH 8, 0.2% NaN3, 1% Triton X-100, 0.2% SDS), 
500 buffer (0.1% Deoxycholic acid, 1 mM EDTA pH 8, 500 mM NaCl, 50 mM HEPES 
pH 7.5, 0.2% NaN3, 1% Triton X-100), LiCl buffer (0.5% Deoxycholic acid, 1 mM 
EDTA, 250 mM LiCl, 10 mM Tris pH 8, 0.2% NaN3, 0.5% NP-40) and TE. DNA was 
eluted in elution buffer and cross-links were reversed by incubation overnight at 
65 ºC. RNA and protein were digested using RNAse A and Proteinase K and DNA 
was purified by phenol-chloroform extraction and isopropanol precipitation. 
Target DNA abundance in ChIP eluates was assayed by quantitative PCR with  
Table 5. List of ChIP-qPCR primers used in this study. Primers for AchR and NOLC1 
were designed at Dr. Bruno Amati laboratory (IFOM, Milan, Italy). 
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primer pairs designed to achieve products of 50-200bp. Primer sequences are 
provided in Table 5. The following antibodies were used: anti-MYC N262 (Santa 
Cruz Biotechnology, sc-764), anti-H3K4me3 (Abcam, ab8580), anti-panAc Histone 
H3 (Merck Millipore, 06-599, Billerica, MA, USA), and anti-total Histone H3 
(Abcam, ab1791). 
3.7. DNAse I hypersensitivity assay 
DNAse I experiments were performed as described previously (Di Stefano et al. 
2014). Briefly, chromatin samples were obtained as described above and 
subjected to DNAse I digestion. Chromatin (2 g) was treated with 0.5, 1, and 2 
units of RQ1 RNase-Free DNAse I (Promega, Fitchburg, WI, USA) for 3 min at 37 
ºC in 1X DNAse incubation buffer. Reactions were terminated by adding 2 mM 
EGTA and the crosslinking was reversed by incubating samples at 65 ºC. After 6h, 
proteinase K (40 mg/ml) was added to each reaction and incubated overnight at 
37 ºC. After phenol-chloroform extraction, DNA was quantified and used as 
template for q-PCR reactions with the same primer pairs used for ChIP-qPCR.   
 
4. GENOME-WIDE STUDIES AND BIOINFORMATICS ANALYSES 
4.1. ChIP-Seq library construction and massive parallel sequencing  
ChIP was performed as described above. DNA (20 ng) was quantified by 
fluorometry, resolved by electrophoresis, and fractions of 50-250bp were 
extracted. Input samples correspond to balanced blends of inputs from selected 
samples. Fractions were processed through subsequent enzymatic treatments of 
end-repair, dA-tailing, and ligation to adapters following Illumina's "TruSeq DNA 
Sample Preparation Guide" (part # 15005180 Rev. C). Adapter-ligated libraries 
were amplified by limited-cycle PCR with Illumina PE primers (12 cycles). The 
resulting purified DNA library was applied to an Illumina flow cell for cluster 
generation (TruSeq cluster generation kit v5) and sequenced on the Genome 
Analyzer IIx with SBS TruSeq v5 reagents following manufacturer's protocols.  
4.2. ChIP-Seq data processing 
Image analysis and per-cycle base-calling was performed with Illumina Real 
Time Analysis software (RTA1.13). Conversion to FASTQ read format with the 
ELAND algorithm (v2e) was performed with CASAVA-1.8 (Illumina). Quality check 
was done via fastqc (v0.9.4, Babraham Bioinformatics). ChIP-seq reads were 
aligned to the human reference genome (GRCh37/hg19, Feb 2009) with Burrows-
Wheeler Aligner (bwa,v0.5.9-r16) allowing 0-1 mismatches. Unique aligned reads 
were converted to BED format. All ChIP and input samples were normalized 
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randomly to the same number of reads (10,512.988). Furthermore, reads were 
directionally extended to 300 bp and, for each base pair in the genome, the 
number of overlapping sequence reads was determined and averaged over a 10 
bp window to create a wig file to visualize the data in the University of California 
Santa Cruz (UCSC) genome browser. The number of significant peaks of MYC 
binding sites was 1762 for sh#1+OHT and 1397 for shNt+OHT, using MACS 
(version 2.0.9 20111102, tag:alpha) and parameters: -g 2.7e9; -m 10,30; -q 0.05.  
4.3. Motif enrichment analysis, peak annotation and density plot analysis 
Motifs for the list of peaks in shNt+OHT were identified with the MEME suite 
and then TOMTOM was used to compare the identified motifs with known 
transcription factor binding motifs. Sequence logos were generated using 
WebLogo 2.8.2. Genomic annotation was carried out with Hypergeometric 
Optimization of Motif EnRichment (HOMER, software v4.2). The tool 
annotatePeaks.pl was used with parameters by default and defined in the help. 
A gtf file from UCSC based on GRCh37/hg19 was used for annotations; the latter 
included whether a segment is in the TSS, TTS, exon, 5' UTR exon, 3' UTR exon, 
intron, or is intergenic. Since some annotations overlap, the following priority was 
assigned: TSS (from -1kb to +100bp), TTS (from -100 bp to +1kb), CDS exon, 5' 
UTR exon, 3' UTR exon, intron, intergenic. More detailed information is available 
in http://homer.salk.edu/homer/ngs/annotation.html. The SeqMINER (v1.3.3e) 
platform (Ye et al. 2010) was used to generate the density read plots shown in 
Fig. 11b. 
4.4. Gene set enrichment analysis (GSEA) 
MYC-bound genes were rank-ordered according to the fold-change in FPKM 
values (4-OHT vs. vehicle) in HFF MYC-ER control cells and then submitted to 
analysis using GSEA software (www.broadinstitute.org/gsea). The list of pre-
ranked genes was analysed with the gene set matrix composed file 
c2.all.v4.0.symbols.gmt and c5.all.v4.0.symbols.gmt. Significant gene sets 
enriched by 4-OHT-treatment of control cells were identified using an FDR q-




Total RNA (1 µg) was spiked with ERCC ExFold RNA spike-In mixes (Life 
Technologies). RNA quality was assessed on an Agilent 2100 Bioanalyzer and 
samples with a RNA Integrity Number > 8.5 were used. PolyA+ fractions were 
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purified, randomly fragmented, converted to double stranded cDNA, and 
processed through subsequent enzymatic treatments of end-repair, dA-tailing, 
and ligation to adapters following Illumina's "TruSeq Stranded mRNA Sample 
Preparation Part # 15031047 Rev. D" (this kit incorporates dUTP during 2nd 
strand cDNA synthesis, which implies that only the cDNA strand generated during 
1st strand synthesis is eventually sequenced). Adapter-ligated libraries were 
generated by PCR with Illumina PE primers (8 cycles). The resulting purified cDNA 
libraries were applied to an Illumina flow cell for cluster generation (TruSeq 
cluster generation kit v5) and sequenced on the Genome Analyzer IIx with SBS 
TruSeq v5 reagents by following manufacturer's protocols. 
4.6. RNA-Seq data processing 
Image analysis and per-cycle base-calling was performed with Illumina Real 
Time Analysis software (RTA1.13). Conversion to FASTQ read format with the 
ELAND algorithm (v2e) was performed with CASAVA-1.8 (Illumina). These files 
contain only reads that passed "chastity" filtering (flagged with a ‘N’, for *NOT 
filtered* in the sequence identifier line). "Chastity" parameter measures signal 
contamination in raw data and allows to flag unreliable reads. Quality check was 
done via fastqc (v0.9.4, Babraham Bioinformatics). Raw reads were aligned to the 
build version GRCh37/hg19 of the human genome where the sequence of the 
ERCC synthetic spike-in RNAs 
(http://tools.invitrogen.com/downloads/ERCC92.fa) had been added. Tophat5 
(version 2.0.4) was used for alignment with the following parameters: --bowtie1, 
--max-multihits 5, --genome-read-mismatches 1 --segment-mismatches 1 --
segment-length 19 --splice-mismatches 0 --library-type fr-firststrand. Gene 
expression levels and synthetic spike-in RNA (Fragments Per Kilobase of exon per 
Million fragments mapped, FPKM) were quantified with cufflinks (version 2.0.2), 
with the following parameters: -N, --library-type fr-firststrand, -u. Further, we 
used a loess regression to renormalize the FPKM values by using only the spike-
in values to fit the loess following the strategy described  (Lovén et al. 2012). The 
affy package in R provides a function, loess.normalize, performing loess 
regression on a matrix of values and allowing to specify which subset of data to 
use when fitting the loess (see the affy package for further details). The result 
was a matrix of FPKM values normalized to the control ERCC spike-ins. 
4.7. RNA-Seq GSEA analysis 
Genes were rank-ordered according to the fold change in FPKM values (4-OHT 
vs Vehicle) in HFF MYC-ER control cells and then submitted to analysis using GSEA 
software (www.broadinstitute.org/gsea). The list of pre-ranked genes was 
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analysed with the gene set matrix composed file c2.all.v4.0.symbols.gmt and 
c5.all.v4.0.symbols.gmt. Significant gene sets enriched by OHT-treatment of 
control cells were identified using an FDR q-value < 0.25 and a nominal P value < 
0.05. All analyses were performed using GSEA v2.1 software with pre-ranked list 
and 1000 data permutations. 
4.8. Analysis of human tumor genomic data 
Gene expression data from 20 studies profiling human tumors were 
downloaded from either Oncomine or GEO (Gene Expression Omnibus). The 
complete list of datasets, together with their GEO accession numbers, is provided 
in Table 7. Expression data for each study were converted into the GenePattern 
GCT format. To obtain one expression value per gene and sample, GCT files were 
subsequently collapsed using the CollapseDataset module in GenePattern. We 
next rank-ordered the samples within each dataset according to the mRNA levels 
of BPTF, c-MYC, N-MYC, or L-MYC and performed a single sample GSEA (ssGSEA) 
to calculate activation scores for 4 MYC-dependent gene signatures in each 
sample. ssGSEA enrichment score represents the degree to which the genes in a 
particular gene set are coordinately up- or down-regulated within a sample. The 
following gene signatures were downloaded from Molecular Signature Database: 
BILD_MYC_ONCOGENIC_SIGNATURE (M2069), ALFANO_MYC_TARGETS 
(M2477), and SCHUHMACHER_MYC_TARGETS_UP. The Seitz signature was built 
from the data published in Seitz et al. 2011. 
 
5. STATISTICAL ANALYSIS 
All quantitative data are presented as mean ± S.E.M. (Standard Error of Mean) 
from >2 experiments or samples per data point (n is mentioned in each figure 
legend). Unpaired student’s t-test (two-tailed) was used to compare two groups 
of independent samples. Paired student’s T-test (two-tailed) was used to 
compare matched pairs samples. To compare the data distribution of two 
separate populations without assuming normal distribution we performed a 
Wilcoxon Signed-Ranked test. For in vitro experiments, sample size required was 
not determined a priori. The experiments were not randomized. 
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1. BPTF IS REQUIRED FOR IN VITRO PROLIFERATION OF TUMOR CELLS 
We first identified BPTF as part of a candidate network of transcription factors 
controlling cell proliferation in two pancreatic ductal adenocarcinoma (PDAC) cell 
lines (SK-PC-1 and IMIM-PC-2) (Vilá et al. 1995). Among the other genes identified 
with this approach there was also GATA6, which has been proven to be a tumor 
suppressor in KrasG12V-driven pancreatic tumorigenesis in mice (Martinelli et al. 
2015). 
The genetic inhibition of BPTF in two additional PDAC cell lines (PK9 and MIA 
PaCa-2) using two shRNAs was associated with impaired proliferation, assessed 
by growth curve and colony-formation assays (Fig. 5). This observation was 
extended to a panel of cell lines established from bladder tumors, a cancer type 
where BPTF is mutated (Balbás-Martínez et al. 2013; González-Pérez et al. 2013). 
These results are in agreement with other reports using human lung embryonal-
derived cells and the T47D-MTVL cell line (Buganim et al. 2008; Vicent et al. 2011).  
Figure 5. BPTF is required for 
cell proliferation of PDAC 
cells. a) Western blotting 
analysis showing BPTF down-
regulation in two PDAC cell 
lines upon transduction of 
BPTF-targeting shRNAs (sh#1 
and #2). Cells expressing a 
non-targeting shRNA (shNt) 
were used as controls. b) 
Colony-formation assays with 
the indicated cell lines 
expressing BPTF-targeting 
shRNAs or their controls. c) 
Impact of BPTF down-
regulation on cell 
proliferation of the indicated 
cell populations. Cells were 
plated at equal numbers at 
day 3 post-infection and cell 
number was quantified 
during the consecutive days 
(mean ± SEM; n=3).  *, P value 
< 0.05; **, P value < 0.01; ***, 




2. BPTF IS MODULATED DURING CELL CYCLE PROGRESSION AND IS 
REQUIRED FOR G0-G1/S TRANSITION 
In order to better understand the role of BPTF in cell proliferation, we took 
advantage of non-transformed non-immortalized human foreskin fibroblasts 
(HFF). Cells were synchronized by starvation and stimulated to re-enter cell cycle 
by serum addition. BPTF levels were modulated as cells progressed through the 
cell cycle, being induced as early as 5 minutes after serum addition and becoming 
maximal in the G1/S transition. Upon entry into S phase, BPTF protein levels 
decreased and became undetectable (Fig. 6a,c). The analysis of mRNA expression  
  
Figure 6. BPTF is modulated during cell cycle progression. Serum-starved HFF were 
stimulated to cycle by FBS addition and collected at the indicated time points. Western 
blotting analysis of total cellular fractions is shown in a) and c). Transit through the different 
cell cycle phases is indicated with arrows. One representative experiment of at least three 
with similar results is shown. Analysis of mRNA levels is shown in b) and e) (mean ± SEM; 
n=3). Transcript levels were normalized against HPRT and the 0h time point.  
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revealed that, unlike cyclins (e.g. D1 and E) or transcription factors classically 
involved in cell cycle control (e.g. c-MYC and AP-1), BPTF mRNA did not change 
significantly throughout the experiment. These data suggest that post-
translational modifications are involved in the regulation of BPTF protein levels 
(Fig. 6b,d).  
BPTF silencing in HFF using two shRNAs led to a decrease in cell proliferation, 
assessed by growth curve (Fig. 7a,b). When BPTF-interfered cells were serum-
starved and challenged to proliferate by FBS stimulation, they expressed lower 
levels of c-MYC and Cyclins D1 and A than control cells (Fig. 7c). According to 
these results, BPTF is necessary for the G0-G1/S transition. 
  
Figure 7. BPTF is required for proliferation of HFF. a) HFF cells expressing control or BPTF-
targeting shRNAs (sh#1 and sh#2) were examined by Western blotting. b) Cells in a) were 
seeded at similar densities at day 3 post-infection and counted at the indicated time points 
(mean ± SEM; n=3). *, P < 0.05. c) HFF cells transduced as in a) were synchronized and 
collected at different time points. Total cellular fractions were assessed by Western 
blotting. Only the data regarding shBPTF#1 is shown. One representative experiment of at 
least three with similar results is shown.  
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3. BPTF IS NECESSARY FOR c-MYC TRANSCRIPTIONAL ACTIVITY 
BPTF modulates gene expression through the interaction with sequence-specific 
transcription factors. The identity of such regulators has been extensively studied 
in Drosophila but only a few have been discovered in murine and human cells 
(Alkhatib and Landry 2011; Qiu et al. 2015). Since BPTF is necessary for cell 
proliferation and, more precisely, for G0-G1/S transition, we hypothesized that its 
effects might be mediated, at least in part, by c-MYC.  
The hypothesis of BPTF as an interactive partner of c-MYC is attractive for 
several reasons. First, c-MYC binding sites are highly enriched in H3K4me3, 
H3K79me2 and H3 acetylation (Guccione et al. 2006; Martinato et al. 2008). This 
open chromatin configuration operates upstream of sequence-recognition by c-
MYC and, most likely, is ‘read’ by c-MYC binding proteins and complexes with 
specialized motifs (bromodomains, PHD fingers or chromodomains). So far, 
however, the protein(s) involved in the recognition of these marks by c-MYC have 
not been identified. Human BPTF contains two PHD fingers and one 
bromodomain that bind to H3K4me2/3 and H4K16ac respectively (Li et al. 2006; 
Ruthenburg et al. 2011), thus making it a plausible candidate. Second, c-MYC has 
long been considered an undruggable oncogene. However, the disruption of 
chromatin-dependent processes that suppress c-MYC activity - such as the 
inhibition of the BET bromodomain protein Brd4 by JQ1 - has recently shown 
promising results in experimental models of multiple myeloma, Burkitt 
Lymphoma (BL), acute myeloid leukemia and acute lymphoblastic leukemia 
(Dawson et al. 2011; Delmore et al. 2011; Mertz et al. 2011). BPTF also contains 
a potentially druggable bromodomain that, if proven relevant for c-MYC function, 
could be exploited in cancer therapy. 
To assess whether BPTF is required for the transcriptional activity of c-MYC, we 
took advantage of the steroid-activatable construct c-MYC-ER. c-MYC-ER is a 
fusion protein in which the ligand-binding domain (ER) of a mutant estrogen 
receptor, G525R (Danielian et al. 1993), is fused to the carboxyl terminus of c-
MYC. ER lacks intrinsic transactivation activity; it responds to the synthetic steroid 
4-hydroxytamoxifen (4-OHT), but not to estrogens (Littlewood et al. 1995). The 
MYC-ER protein is constitutively expressed but it is sequestered in the ctytoplasm 
unless 4-OHT is supplied. Upon addition of 4-OHT, MYC-ER induces proliferation 
and apoptosis in the same manner as wild-type MYC (Littlewood et al. 1995; 
Alarcon et al. 1996).  
HFF were stably transduced with the chimeric MYC-ER cDNA (HFF MYC-ER) and 
infected with lentiviruses coding for either control (shNt) or BPTF-targeting 
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shRNAs (sh#1 and sh#2). Before treatment with 4-OHT, cells were serum-starved 
for 2 days to achieve quiescence, ruling out proliferation-associated effects. 
Immunofluorescence analysis confirmed that the lentiviral shRNAs inhibited the 
expression of BPTF and did not interfere with MYC-ER nuclear translocation (Fig. 
8a).  
Figure 8. BPTF is required for c-MYC transcriptional activity. a) Immunofluorescence 
staining of BPTF and c-MYC showing MYC-ER nuclear translocation upon 4-OHT treatment 
in control and BPTF-silenced HFF. b) Examples of expression of known c-MYC target genes, 
analysed by RT-qPCR, upon BPTF knockdown. Transcript levels were normalized against 
GAPDH and the vehicle-treated condition. Data are expressed as the mean  SEM (n ≤ 5). 
P value was determined using an unpaired T-test. c) Diagram showing the Bptf floxed allele 
and assessment of Cre-mediated recombination at the DNA level. d) Excision of Bptf exon 
2 does not decrease the expression of BPTF at the mRNA level. Instead, it gives rise to two 
out-of-frame mutant mRNA species that can be specifically detected by RT-qPCR. e) 
Expression of a set of c-MYC target genes in WT and Bptf-null MEFs (n ≥ 4) expressing MYC-
ER. Cells arrested with 0.5% FBS for 24h were treated for the indicated time with 10% FBS 
with or without 4-OHT 2 M. Data are represented as the mean  SEM. P value was 




Next, we analysed the expression of a set of well-established c-MYC targets by 
RT-qPCR. BPTF knockdown resulted in a significantly impaired mRNA induction of 
6/7 c-MYC targets tested with at least one of the two shRNAs (Fig. 8b). To extend 
these findings, we used Bptf-null MEFs (Landry et al. 2008) transduced with MYC-
ER. Successful recombination of the floxed allele was demonstrated by PCR and 
RT-qPCR analysis (Fig. 8c,d). In these cells, addition of 4-OHT also resulted in an 
impaired activation of 4 well-documented c-MYC targets (Neri et al. 2012) (Fig. 
8e). 
Next, RNA-Seq was performed to evaluate the requirement of BPTF for the 
activation of the full c-MYC-driven transcriptional program in HFF MYC-ER cells. 
BPTF knockdown in HFF MYC-ER cells resulted in a reduced transcriptional 
response to 4-OHT, both up- and down-regulated genes being significantly 
affected (Fig. 9a). We interrogated the genes differentially expressed in control 
cells treated with either vehicle or 4-OHT with publicly available gene signatures 
using Gene Set Enrichment Analysis (GSEA). Genes up-regulated upon 4-OHT 
addition showed a statistically significant enrichment in c-MYC-dependent 
transcriptional signatures (Schuhmacher et al. 2001; Schlosser et al. 2005; Acosta 
et al 2008) and Gene Ontology (GO) pathways classically associated with c-MYC 
function (i.e. ribosome biogenesis and translation, mitochondrial function, and 
RNA/rRNA/tRNA processing). Conversely, genes down-regulated in 4-OHT-
treated cells overlapped with gene sets known to be repressed by c-MYC (Kim et 
al. 2006; O’Donnell et al. 2006) (Fig. 9b and Table 6). 
The mechanisms involved in c-MYC-mediated repression have not been fully 
elucidated; therefore, we focused on its best established role as a transcriptional 
activator (Lovén et al. 2012). We found an impaired activation of 5 independent 
c-MYC signatures in BPTF-silenced cells (Fig. 9c). These results were validated by 
RT-qPCR for an additional 20 genes, 19 of which are c-MYC ChIP-Seq targets in at 
least one cell line profiled by ENCODE. The extent of induction of these genes was 
significantly reduced in HFF MYC-ER cells transduced with both BPTF-targeting 
shRNA lentiviruses [average fold-change (4-OHT vs. vehicle) for shNt, 2.44; sh#1, 
1.52; sh#2, 1.97] [P (shNt vs. sh#1) < 0.0001; P (shNt vs. sh#2) = 0.0485] (Fig. 9d). 








Figure 9. Genome-wide analysis of BPTF-dependent c-MYC transcriptional activity. a) 
Fold-change in FPKM values (vehicle vs. 4-OHT) of up-regulated [Log2 F.c. ≥ +1] and down-
regulated [Log2 F.c. ≤ -1] genes in control and BPTF-silenced cells. b) Snapshots of MYC-
dependent gene sets displaying a positive or a negative enrichment in 4-OHT-treated 
control cells. c) Fold-change in FPKM values of c-MYC-dependent gene sets enriched in 4-
OHT-treated control cells. Values are displayed for both control and BPTF-silenced HFF 
MYC-ER cells. Gene sets tested and P values: 1, Schuhmacher et al. ‘MYC Targets Up’ (P = 
3.156·10-15); 2, Acosta et al. ‘Proliferation Independent MYC Targets Up’ (P = 2.034·10-08); 
3, Schlosser et al. ‘MYC Targets Serum Response Up’ (P = 6.62·10-09); 4, Schlosser et al. ‘MYC 
Targets Serum Response Dn’ (P = 6.11·10-09); 5, Schlosser et al. ‘MYC Targets Repressed By 
Serum’ (P = 2.747·10-14). d) Fold-change in mRNA levels for the set of 20 genes used for 
validation. Left panel: data calculated from FPKM values. Right panel: data calculated from 
≥3 independent experiments assessed by RT-qPCR. e) Examples of genes included in the 
validation. Transcript levels were normalized against GAPDH and the vehicle-treated 
condition. Data are expressed as the mean  SEM. *, P value < 0.05; **, P value < 0.01; ***, 




4. BPTF AND c-MYC INTERACT IN VITRO 
While this work was being performed, BPTF was also identified as a putative c-
MYC interactor in a genome-wide proteomic approach (Agrawal et al. 2010). To 
determine whether the effects observed on transcription could result from the 
interaction between c-MYC and BPTF, 293T cells were transiently transfected 
with plasmids encoding HA-MYC and Flag-BPTF. Immunoprecipitation of BPTF 
followed by Western blotting revealed that both proteins are present in the same 
complex (Fig. 10a). The interaction between endogenous c-MYC and BPTF was 
validated in MIA PaCa-2 pancreas cancer cells, expressing high levels of both 
proteins, using in situ proximity ligation assay (isPLA) and home-made affinity-
purified rabbit polyclonal antibodies recognizing residues 913-942 of human BPTF 
(Fig. 10b). Together, these results strongly suggest that c-MYC and BPTF interact 
directly in vivo and that this interaction could contribute to explain the defective 




Table 6. Top-ranking gene sets enriched in 4-OHT-treated control cells. Genes were pre-
ranked according to their FPKM fold change (4-OHT/Vehicle) and then submitted to GSEA. 
The upper group represents curated gene sets (MSigDB collection 2), while the bottom 
group represents GO gene sets (MSigDB collection 5). MYC-dependent signatures are 




5. GENOME-WIDE ANALYSIS OF c-MYC RECRUITMENT TO DNA UPON BPTF 
KNOCK-DOWN 
To identify the mechanisms through which BPTF knockdown attenuates the c-
MYC transcriptional response in HFF MYC-ER cells, we conducted chromatin 
immunoprecipitation with antibodies specific for c-MYC followed by massive 
parallel sequencing (ChIP-Seq) (Fig. 11a). A total of 1397 peaks were identified in 
4-OHT-treated cells. In agreement with previous reports, the analysis of the 
density profiles of the distance between the summit of peaks and gene 
transcription start sites (TSS) showed that c-MYC binding sites were concentrated 
around the TSS (Fernandez et al. 2003; Perna et al. 2012). Sequence analysis of c-
MYC-targeted regions with MEME (Bailey et al. 2009) unveiled a significant over-
representation of the MYC:MAX binding motif (P = 2,8·10-69) (Fig. 11b). ChIP peaks 
occurred within promoter regions (TSS±3kb) (35.6%), gene bodies (intragenic) 
(25%), and further upstream or downstream (intergenic) (39.4%) (Fig. 11c). 
Moreover, GSEA analysis of c-MYC-bound promoters showed highly statistically 
significant overlap with 3 transcriptional signatures of c-MYC-dependent genes 
and with biological modules associated with c-MYC function (e.g. cell 
proliferation) (Fig. 11d,e). Induction at the mRNA level of genes directly bound by 
c-MYC was significantly higher than of those lacking a ChIP-Seq peak (Fig. 11f). 
Figure 10. Analysis of c-MYC:BPTF interaction. a) Coimmunoprecipitation of Flag-BPTF 
with HA-tagged c-MYC from lysates of transiently transfected 293T cells; Western blotting 
with the indicated antibodies. b) Endogenous BPTF and c-MYC interact directly in MIA 
PaCa-2 cells as shown by in situ proximity ligation assay PLA. The interaction events are 
visible as red dots (nuclear staining in blue) and are marked by arrowheads. The interaction 
of MYC with MAX is shown as a positive control. Number of dots per nuclei was quantified 




Figure 11. Analysis of MYC-ER recruitment to chromatin in control cells. a) Summary 
of high-quality reads obtained per condition. b) Density profile of c-MYC binding sites 
relative to TSS. All binding sites within  6kb were included in the analysis. TSS distance 
is measured as the relative base pair distance to peaks’ summit. MEME motif prediction 
of DNA sequences enriched in c-MYC ChIPseq in 4-OHT-treated shNt cells. c) Distribution 
of c-MYC binding sites relative to the gene bodies of Ref Seq annotated transcripts. d) 
Snapshots of c-MYC-dependent gene sets enriched among c-MYC-bound promoters in 
control cells. e) Top-ranking gene sets enriched in MYC-bound promoters pre-ranked 
according to their FPKM fold change (4-OHT-treated vs. vehicle-treated). The upper 
group represents curated gene sets (MSigDB collection 2), while the bottom group 
represents GO gene sets (MSigDB collection 5). MYC-dependent signatures are 
highlighted in red. NES: Normalized Enrichment Score; FDR: False Discovery Rate. f) 
Fold-change in FPKM values (4-OHT vs vehicle) for genes bound by c-MYC (with a ChIP-
Seq peak within ± 3kb TSS) and genes not bound, both in control and BPTF-silenced cells. 




To determine whether BPTF silencing interfered with c-MYC recruitment to 
chromatin, we analysed the magnitude and distribution of c-MYC ChIP-Seq peaks 
upon BPTF knockdown in HFF. Globally, c-MYC binding intensity was significantly 
lower in shBPTF-expressing cells (P < 2.2·10-16) (Fig. 12a,b). This reduction was not 
evenly distributed at the genome wide level, with 50.2% of the peaks showing a 
read number fold-change ≥ 2. The selective effect of BPTF silencing on a subset 
of c-MYC ChIP-Seq peaks -regardless of their intensity- suggests that the 
differences do not result from an inefficient ChIP. We validated these 
observations by ChIP-qPCR on gene promoters for which a peak was identified in 
the ChIP-Seq experiment ("target"), as well as on a set of “non-target” control 
genomic regions, in at least 3 independent experiments. c-MYC was recruited to 
target regions and did not show significant binding to non-target promoters. c-
MYC recruitment to target genes was significantly reduced in cells infected with 
the BPTF-targeting shRNAs (Fig. 12c,d). High-affinity MYC targets (Fernandez et 
al. 2003; Guccione et al. 2006; Perna et al. 2012) were significantly enriched 
among the genes for which BPTF silencing had more effect on c-MYC recruitment 
(Fig. 12e). The effect of BPTF silencing on the induction of c-MYC target mRNAs 
was independent from the extent of reduction in c-MYC binding at their 
promoters (Fig. 12f), suggesting that BPTF operates downstream of c-MYC in the 





Figure 12. BPTF silencing interferes with c-MYC recruitment to its target genes. a) Box 
plot showing the intensity of c-MYC ChIP-seq signal (reads/peak) at MYC-enriched regions 
in control and BPTF-silenced HFF MYC-ER cells. MYC-enriched regions were defined in 4-
OHT-treated control cells. c-MYC binding intensity was measured as number of reads per 
peak. P value was determined using a Wilcoxon test. b) Representative snapshots of c-MYC-
bound genomic regions in control and BPTF-silenced HFF MYC-ER cells after stimulation 
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with 4-OHT. c) ChIP analysis of c-MYC enrichment at the promoters of “Target” and 
“Non-target” genes in control and BPTF-silenced HFF MYC-ER cells in the presence 
(white) or absence of 4-OHT (black). ChIP values are expressed as average ± SEM of % 
input chromatin (n ≥ 3). An isotype-matched IgG antibody was used as control (lower 
panels). d) Fold-change in % of input following c-MYC induction, averaged for the two 
different promoter populations in control and BPTF-silenced cells. e) High-affinity MYC-
targets are significantly enriched among the genes for which MYC recruitment is less 
affected by BPTF knockdown. f) c-MYC target genes ranked according to the change in 
c-MYC binding at their promoters after BPTF silencing. BPTF-dependency of c-MYC 
recruitment to DNA is calculated as the Log2 (Reads shBPTF/Reads shNt) (left y-axis). For 
the same collection of ranked genes, the transcriptional response to 4-OHT is shown 
(scatter plot right y-axis). BPTF-dependency of 4-OHT-dependent mRNA induction is 
calculated as the Log2 (F.c. shBPTF/F.c. shNt). 4 data points are outside the right y-axis 
limits. *, P value < 0.05; **, P value < 0.01; ***, P value < 0.001. 
 
6. BPTF IS REQUIRED FOR c-MYC-INDUCED REMODELLING OF TARGET 
CHROMATIN 
c-MYC activates gene expression by recruiting, among others, HATs and 
chromatin-modifying complexes resulting in histone hyperacetylation, 
nucleosome displacement, and increased promoter accessibility (Lüscher and 
Vervoorts 2012). Bromodomain-containing proteins, such as BRD4, recognize 
acetylated histones and facilitate transcriptional activation through the 
recruitment of P-TEFb (Yang et al. 2005). To assess whether BPTF knockdown led 
to changes in DNA accessibility, we performed quantitative DNAse I 
hypersensitivity assays, as described earlier (Di Stefano et al. 2014). DNAse I 
hypersensitive sites mark cis-regulatory elements (i.e. enhancers or promoters) 
and result from the cooperative binding of transcription factors and chromatin-
remodelling complexes (Thurman et al. 2012).  
We analysed the DNA accessibility of c-MYC “Target” promoters validated in Fig. 
12c in the presence or absence of 4-OHT and included “Non-target” regions for 
comparison. 4-OHT addition to HFF MYC-ER cells led to an increased sensitivity to 
DNAse I (DDHS) of “Target” regions in control (P < 0.001) but not in BPTF-silenced 
cells (Fig. 13a Top). There was no consistent effect on “Non-target” promoters 
(Fig. 13a Bottom). Overall, these results indicate that attenuation of the c-MYC 
transcriptional response is associated with changes in DNA accessibility, 
suggesting that BPTF is necessary for the c-MYC-induced remodelling of target 






We next analysed the levels of acetylated H3 and H3K4me3 in “Target” and 
“Non-Target” promoters by ChIP-qPCR. As reported previously, c-MYC activation 
in control cells resulted in the selective hyperacetylation of histone H3 in “Target” 
promoters (P = 0.002). Importantly, this effect was lost upon BPTF knockdown 
(Fig. 14a Top). By contrast, the levels of H3K4me3 were unaffected by BPTF 
silencing (Fig. 14b Bottom).  
 
Figure 13. BPTF silencing 
limits DNA accessibility at c-
MYC target promoters. a) 
DNAse I sensitivity at MYC-
bound regions in control 
and BPTF-silenced HFF MYC-
ER cells, determined by 
enzyme titration. Dots 
represent the average 
values of 7 independent 
experiments. P values were 
determined using paired t-
test. *, P value < 0.05; **, P 
value < 0.01; ***, P value < 
0.001. 
 
Figure 14. BPTF is required 
for c-MYC-induced 
hyperacetylation of target 
promoters. a) ChIP analysis 
of Pan AcH3 (Top) and 
H3K4me3 (Bottom) levels at 
the promoter of “Target” 
and “Non-target” genes in 
control and BPTF-silenced 
HFF MYC-ER cells. ChIP 
values are expressed as % of 
input and normalized for 
total histone H3. P values 
were determined using 
paired t-test. *, P < 0.05. **, 




7. BPTF IS REQUIRED FOR A SUBSET OF c-MYC BIOLOGICAL FUNCTIONS 
MYC proteins regulate a wide variety of biological processes including cell 
growth, proliferation, differentiation, and apoptosis. Physiological c-MYC levels 
induce DNA synthesis through the transcriptional activation of cell cycle-related 
genes (Liu et al. 2008b) and by modulating the activity of DNA replication origins 
(Dominguez-Sola et al. 2007). c-MYC overexpression and/or deregulation is 
associated with unscheduled firing of DNA replication origins, DNA damage 
response, and checkpoint activation (Murga et al. 2011).  
To determine whether BPTF is required for the proliferation-related effects of 
c-MYC, we used wild type (WT) and Bptf-null MEFs. Cells were co-infected with 
lentiviruses coding for Cre recombinase and the MYC-ER fusion protein. 
Quiescent MEFs were induced to re-enter the cell cycle by addition of FBS±4-OHT 
and S phase entry was assessed by BrdU uptake. 4-OHT-treated WT and Bptf-null 
cells showed a significantly higher percentage of cells in S phase than vehicle-
Figure 15. BPTF is required for MYC-induced proliferation of MEFs. a) WT and Bpft-null 
MEFs transduced with MYC-ER were seeded at high density, arrested with 0.5% FBS for 
48h, and stimulated with serum in the presence/absence of 4-OHT. At indicated time 
points, cells were pulse-labelled with BrdU for 1h before harvesting. b) Histograms 
depicting the ploidy of BrdU+ cells throughout the experiment described in panel (a). c) 
Quantification of early S phase cells. The rate of loss of BrdU+ early S-phase cells 
represents S-phase progression. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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treated cells as early as 9h after FBS+4-OHT stimulation (P = 0.014), indicative of 
MYC-induced G1/S progression (Fig. 15a). DNA content analysis of BrdU+ cells 
followed by quantification of cells in early S phase showed that BPTF deletion 
resulted in a significantly delayed progression through S phase in MYC-ER-
activated cells (at 18h, P < 0.001). There were no effects in vehicle-treated cells 
(Fig. 15b,c). 
c-MYC overexpression can induce replication stress (Murga et al. 2011). Adding 
4-OHT to WT MYC-ER MEFs led to an accumulation of cells with high levels of pan-
nuclear H2AX (P = 0.017), indicative of replication stress, whereas no effect was 
observed in Bptf-null cells (Fig. 16a). c-MYC can also induce apoptosis when 
expressed from an ectopic promoter in the presence of limiting survival signals or 
upon cell stress (Evan et al. 1992). To assess whether BPTF is required for MYC-
induced apoptosis, WT and Bptf-null MYC-ER MEFs were seeded at high density 
and cultured in 0.5% FBS containing either vehicle or 4-OHT. Apoptosis was 
quantified by Annexin V staining and DAPI exclusion. MYC-ER activation triggered 
a robust apoptotic response in Bptf-null MEFs that was indistinguishable from 
that observed in wild-type cells (Fig. 16b).  
 
 
Therefore, BPTF silencing distinctly affects a subset of c-MYC biological 
functions. To activate cell proliferation, c-MYC binds directly to genes involved in 
DNA replication and cell cycle control (i.e. MCM5, MCM6 or DBF4) and enhances 
Figure 16. BPTF is required for c-MYC-induced replicative stress but not for apoptosis. a) 
Replication stress - Intensity of H2AX signal in WT and Bpft-null MYC-ER MEFs (n=3/group) 
in the presence or absence of 4-OHT for 48h. Doxorubicin-treated cells were used as 
control. b) WT and Bpft-null MEFs expressing MYC-ER were seeded at high density and then 
transferred to 0.5% FBS with or without 4-OHT (2M). Apoptosis was measured as the 
proportion of Annexin-postivive cells at the indicated time points by Annexin V staining. *, 
P value < 0.05; **, P value < 0.01; ***, P value < 0.001. 
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their transcription (Perna et al. 2012). By contrast, c-MYC-driven apoptosis is 
indirect and involves the stabilization of p19ARF and p53 or the down-regulation 
of anti-apoptotic BCL-2 through inhibition of the transcriptional activator MIZ-1 
(Hoffman and Liebermann 2008). We therefore propose that BPTF is only 
required for those c-MYC functions involving direct binding to chromatin.  
 
8. BPTF IS REQUIRED FOR THE REPROGRAMMING OF MOUSE 
EMBRYONIC FIBROBLASTS 
The combined transduction of fibroblasts with OCT4, SOX2, KLF4, and c-MYC 
(OSKM) can reprogram fibroblasts to induced pluripotency (Takahashi et al. 
2007). Ectopic c-MYC expression is dispensable for reprogramming of somatic 
cells although, in combination with OSK, facilitates the emergence of rare 
reprogrammed cells. c-MYC has been shown to exert its role during the first days 
of the reprogramming process, since its depletion after day 5 does not 
significantly alter the eventual number of iPS colonies (Sridharan et al. 2009). 
Interestingly, two independent studies have shown that BPTF protein and mRNA 
increase during the first 3 days of reprogramming (Fig. 17a) (Soufi et al. 2012; 
Hansson et al. 2012). In addition, a genome-wide study of OSKM occupancy 
revealed that the Bptf promoter is bound by the 4F within the first 48h of 
reprogramming. In agreement with this, RNA analysis of wild type MEFs infected 
with each of the 4F individually showed that BPTF mRNA is rapidly induced by 
each factor in the reprogramming cocktail (Fig. 17b). 
 
 
Figure 17. BPTF mRNA is induced during reprogramming of fibroblasts into iPS cells. 
a) Expression profile of BPTF over the course of a reprogramming experiment (data 
from Hansson et al. 2012). b) Analysis of BPTF mRNA levels in wild-type MEFs infected 
with either c-MYC, SOX2, KLF4 or OCT4. mRNA levels were normalized against HPRT 
and non-transduced MEFs. Data are represented as mean ± SEM (n=2). 
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We thus sought to determine whether BPTF depletion had a differential impact 
on the efficiency of OSKM (4F) and OSK (3F) reprogramming protocols. We used 
wild type and Bptf-null MEFs via 4F and 3F reprogramming. In order to assess 
both the kinetics and the efficiency of the process, we counted the colonies with 
ES-like morphology over the course of the experiment and, in addition, scored 
the yield of alkaline phosphatase (AP) positive colonies between days 12 and 14. 
The kinetics and efficiency of 4F reprogramming in a series of independent MEF 
cultures was significantly impaired in the absence of BPTF (Fig. 18a,b). These 
results were corroborated by reprogramming wild type MEFs with either control 
Figure 18. BPTF is required for optimal OSKM reprogramming efficiency. a) Kinetics 
of appearance of colonies with iPS morphology of WT and Bptf-null MEFs infected 
with 4F. Data correspond to mean ± S.E.M.; n, independent MEF isolates. b) Number 
of AP-positive colonies obtained at 12 day post-infection; mean ± S.E.M (left). 
Representative wells of AP-positive colonies, showing reduced reprogramming 
efficiency in Bptf-null MEFs (right). c) Fold-change of reprogramming efficiency of 
primary WT MEFs retrovirally infected with 4F plus control (shNt) or a BPTF-targeting 
shRNA. Data correspond to the average ± S.E.M. d) Number of AP-positive colonies 
obtained at 12 day post-infection; mean ± S.E.M (left). Representative wells of AP-
positive colonies, indicating reduced reprogramming efficiency in BPTF-silenced 




or a BPTF-targeting shRNA (Fig. 18c,d). Similar observations were made when c-
MYC was removed from the reprogramming cocktail (Fig. 19).  
 
To confirm that the iPS colonies arising from Bptf-null MEFs had indeed 
undergone recombination, we picked colonies with ES-like morphology (n=60) 
from multiple MEF cultures and assessed the extent of recombination of the Bptf 
allele via PCR on genomic DNA. Strikingly, the majority of colonies were either 
escapers or heterozygous for the recombined allele; only one colony was a 
complete knock-out (Fig. 20a,b). Fig. 20c portrays representative pictures of iPS 
colonies of different genotype after expansion on feeders. Both the heterozygous 
Figure 19. BPTF is required for optimal OSK reprogramming efficiency. a) Kinetics of 
appearance of colonies with iPS morphology of WT and Bptf-null MEFs infected with 
3F. Data correspond to mean ± S.E.M.; n, independent MEF isolates. b) Number of 
AP-positive colonies obtained at 14 day post-infection; mean ± S.E.M (left). 
Representative wells of AP-positive colonies, indicating reduced reprogramming 
efficiency in Bptf-null MEFs (right). c) Fold change of reprogramming efficiency of 
primary WT MEFs retrovirally infected with 3F plus control (shNt) or a BPTF-targeting 
shRNA. Data correspond to the average ± S.E.M. d) Number of AP-positive colonies 
obtained at 14 day post-infection; mean ± S.E.M (left). Representative wells of AP-
positive colonies, indicating reduced reprogramming efficiency in BPTF-silenced 




and the Bptf-null iPS expressed lower levels of Nanog, Sox2 and Oct4 when 
compared to wild type (Fig. 20d). Overall, these results indicate that loss of BPTF 
significantly impairs reprogramming. Although we have not reported any 
differences between the 4F and 3F protocol, we cannot rule out the possibility 
that the observed effects are due to the loss of c-MYC function, since the 
endogenous c-MYC protein is likely to play a key role in the reprogramming 




Figure 20. BPTF is required for the reprogramming of mouse fibroblasts. a) Assessment of 
Cre-mediated recombination of the Bptf allele by PCR on genomic DNA from a panel of 
colonies arising from Bptf-null MEFs. Colonies were picked from different MEF 
preparations and reprogramming protocols. b) Quantitation of the percentage of colonies 
with the indicated genotypes in the MEF cultures reprogrammed in (a). c) Representative 
pictures of colonies of the corresponding genotypes after expansion in vitro. d) RT-PCR 




9. BPTF CORRELATES WITH c-MYC SIGNATURES IN HUMAN CANCER 
c-MYC expression is deregulated in the majority of human tumors through a 
variety of mechanisms, including amplification, translocations, and aberrant 
activation of upstream signalling pathways (Dang 2012). A paradigm of c-MYC-
addicted tumors is Burkitt lymphoma (BL), characterized by chromosomal 
translocations leading to c-MYC overexpression under the control of Ig regulatory 
sequences (Taub et al. 1982). Interestingly, BL cell lines express high BPTF mRNA 
levels compared to other tumor types (Fig. 21). BPTF knockdown in two BL cell 
lines, NAMALWA and RAJI, significantly impaired cell proliferation and was 
accompanied by a reduction in the mRNA levels of c-MYC target genes (Fig. 22). 
These results indicate that BPTF is required for the growth of c-MYC-addicted BL 
cells. 
 
Figure 21. BPTF and c-MYC expression in a panel of human cancer cell lines. a) Top: Box 
plot showing the relative BPTF mRNA levels across the different tumor types, extracted 
from CCLE_Expression_Entrez_ID_2186, with gene-centric robust multiarray analysis-
normalized mRNA expression data. Bottom: Box plot showing the relative c-MYC mRNA 
levels across a panel of human cell lines, extracted from CCLE_Expression_Entrez_ID_4609. 




To gain further insight into the relevance of the c-MYC:BPTF axis in human 
cancer, we compared the levels of BPTF and c-MYC with the activation of c-MYC 
gene signatures in a collection of 20 expression datasets encompassing human 
tumors of diverse origin (Table 7). Our analyses included tumor types known to 
be driven by different MYC family members: BL, colorectal, prostate, and 
pancreatic tumors are mainly driven by c-MYC (Taub et al. 1982; Sansom et al. 
2007; Taylor et al. 2010; Saborowski et al. 2014) whereas medulloblastoma and 
ovarian carcinoma commonly show amplification and/or overexpression of N-
MYC and L-MYC, respectively (Garson et al. 1989; Wu et al. 2003). BPTF is over-
expressed in tumors together with c-MYC and, in some cases, N-MYC and L-MYC 





Figure 22. BPTF is required for proliferation of 
c-MYC-dependent cells. a) Effective knockdown 
of BPTF in two BL cell lines (NAMALWA and RAJI), 
assessed by RT-qPCR. Transcript levels were 
normalized against GAPDH and the sh-control 
samples. b) Proliferation analysis of the 
indicated cell lines transduced with control or 
BPTF-targeting shRNAs. Data are expressed as 
the mean  SEM. c) Relative expression of c-MYC 
target genes in BL cell lines transduced with 
sh#1. Transcript levels were normalized against 






Table 7. Summary of human tumor datasets.  
Figure 23. Co-expression of BPTF and MYC genes in human tumors. a) Position of BPTF, c-
MYC, MYCN and MYCL1 mRNAs within the lists of transcribed genes rank-ordered by their 
expression values in a collection of human tumors. 
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Samples within each data set were rank-ordered by the mRNA levels of either 
BPTF, c-MYC, N-MYC or L-MYC and then interrogated by single-sample GSEA 
(ssGSEA) (Barbie et al. 2009) for enrichment of four c-MYC  gene sets showing a 
modest degree of overlap (Fig. 24a). c-MYC signatures correlated with c-MYC 
expression levels in BL, colorectal, prostate, and pancreatic carcinomas. In these 
tumors, BPTF expression levels also correlated positively with c-MYC signatures 
and BPTF knockdown resulted in a marked decrease in proliferation and colony 
formation by pancreatic cancer cells (Fig. 5 and 24b).  
By contrast, c-MYC expression signatures correlated with N-MYC and L-MYC 
expression levels only in medulloblastoma and ovarian carcinoma, respectively, 
and in these tumors the signatures correlated negatively with BPTF expression 
levels (Fig. 24b,c). These data point to a selective role of BPTF in the activation of 








Figure 24. BPTF expression correlates with c-MYC signatures in human tumors. a) Venn 
diagram showing the overlap of the c-MYC signatures used in the following analyses. b) 
Dot plot of Normalized Enrichment Scores (NES) of the 4 c-MYC signatures based on 
GSEA. NES values were calculated for each data set previously ranked-ordered by either 
BPTF or c-MYC levels. c) Volcano plots of NES and enrichment P values of c-MYC 
signatures based on GSEA. NES values were calculated for each data set previously 
ranked-ordered by either BPTF, c-MYC, N-MYC or L-MYC mRNA levels. Filled circles 
represent gene sets with a FDR < 0.25. 
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10. BPTF IS REQUIRED FOR c-MYC-DRIVEN PANCREATIC TUMORIGENESIS 
Transgenic mice in which c-MYC is overexpressed under the control of the 
acinar-specific elastase 1 promoter (Ela-Myc) develop mixed acinar/ductal 
pancreatic adenocarcinomas between 2 and 7 months of age (Sandgren et al. 
1991). To investigate the role of BPTF in c-MYC-driven pancreatic neoplasia, we 
generated Bptflox/lox;Ptf1a+/KI;Ela-Myc+/T mice (BptfP-/-;Ela-Myc) where BPTF is 
deleted in Ptf1a+ pancreatic progenitors around day E9.5-10. In agreement with 
previous reports showing highly efficient recombination mediated by Ptf1a-Cre 
in the pancreas (Martinelli et al. 2013), we detected full recombination of the Bptf 
allele in BptfP-/- mice by PCR and RT-qPCR analysis (Fig. 25a). At 9-12 weeks,     
BptfP-/- pancreata were histologically indistinguishable from controls (Fig. 25b). 
The analysis of mRNA of a panel of acinar, ductal and endocrine markers did not 
unveil important differences either, thus suggesting that BPTF is dispensable for 
pancreatic development after e10.5 (Fig. 25c).  
Figure 25. BPTF deletion has no impact on normal pancreas homeostasis. a) PCR on 
genomic DNA showing efficient recombination at the Bptf locus in BptfP-/- pancreas 
(top). RT-qPCR analysis of BPTF WT and mutant mRNA species in control (n=6) and 
BptfP-/- (n=7) mice (bottom). b) Hematoxylin-eosin staining of wild type and BptfP-/- 
mouse pancreatic sections. V: Blood vessel; D: Duct; *: Islet of Langerhans. c) mRNA 
expression of acinar transcription factors, digestive enzymes and endocrine and 
ductal markers in pancreata of WT and BptfP-/- mice assessed by RT-qPCR (n=3). 
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In contrast, BptfP-/- mice where c-MYC was overexpressed in acinar cells were 
significantly smaller in size (Fig. 26a) and displayed extensive pancreas atrophy. 
The exocrine compartment was almost completely lost and replaced by fat as 
soon as 4 weeks of age (Fig. 26b). The response to glucose overload was normal, 
indicating preservation of endocrine function (Fig. 26c). Transdifferentiation of 
acinar cells into adipocytes has been reported elsewhere (Martinelli et al. 2013; 
Bonal et al. 2009); whether this is the mechanism behind the presence of fat in 
BptfP-/-;Ela-Myc mice remains to be determined.  
In order to better discriminate the effects of BPTF loss on pancreatic cancer, we 
generated Bptflox/lox; Ptf1a-CreERT2+/KI; Ela-Myc mice where recombination of the 
Bptf allele is induced upon oral delivery of 4-OHT. This mouse model allows to 
delay Bptf inactivation and to more effectively assess its role in the early stages 
of the disease. Tamoxifen administration to 5-7 weeks-old mice resulted in 
recombination of 60-70% of the Bptf allele as assessed by PCR on genomic DNA 
(Fig. 27a). A cohort of 10 BptfP+/+;Ela-Myc, 5 BptfP-/+;Ela-Myc and 8 BptfP/-;Ela-Myc 
mice was monitored once a week by ultrasound for pancreas cancer 
development. Animals were sacrificed when tumor burden reached ethical end-
points or showed overt signs of morbidity. BptfP+/+; Ela-Myc mice displayed a 
Figure 26. c-MYC overexpression in Bptf-null mouse pancreata results in extensive 
loss of the acinar compartment. a) Picture showing reduced body size of a BptfP-/- 
mouse (right) when compared to a control mouse (left). e) Hematoxylin-eosin 
staining of mouse pancreatic sections of the indicated genotype showing extensive 
acinar loss in BptfP-/- mice. f) Glycaemia after intraperitoneal glucose injection, in 




typical course of pancreatic cancer development, with a mean disease-free 
survival of 13 weeks. In contrast, BptfP-/+ and BptfP-/- Ela-Myc mice showed 
delayed tumor onset and corresponding extensions in lifespan (P = 0.017) (Fig. 
27b). Moreover, analysis of tumor volume revealed that control mice developed 
pancreatic tumors faster than BptfP-/+ and BptfP-/-;Ela-Myc (Fig. 27c). Finally, we 
evaluated by PCR the genotype of tumors arising in BptfP-/+ and BptfP-/- Ela-Myc 
mice and seen that the majority were escapers or else had a low percentage of 
recombination (Fig. 27d). In summary, BPTF is necessary for the establishment 
and/or maintenance of c-MYC-driven pancreatic tumors. 
 
 
Figure 27. BPTF loss delays the onset of c-MYC driven pancreatic tumors. a) PCR on 
pancreas (P) genomic DNA assessing the extent of recombination at the Bptf locus in 
5-7 weeks-old Ptf1a-CreERT2+/KI; Ela-Myc mice of the corresponding genotypes. Liver 
(L) samples were used as negative controls. b) Kaplan-Meier curves of tumor-free 
survival are shown for Ela-Myc mice of the indicated Bptf genotypes. P value was 
determined using a Log-rank test. c) Tumor volume of Ela-Myc mice of the indicated 
Bptf genotypes as determined by ultrasound. d) PCR analysis of genomic DNA from 










We initially identified BPTF as an element of a network of transcription 
regulators whose expression was modulated during proliferation/cell cycle arrest 
of two pancreatic cancer cell lines. In agreement with our in silico prediction, BPTF 
down-regulation in these cells was associated with impaired proliferation. We 
have expanded this observation to other human cancer cell lines (bladder and 
Burkitt lymphoma) and to non-transformed, non-immortalized human 
fibroblasts. Based on these findings, we focused on the study of its biological 
functions.  
 
1. BPTF AND CELL PROLIFERATION 
In quiescent human fibroblasts, BPTF depletion impedes cells from progressing 
into S phase and completing cell cycle. Of note, Bptf-null MEFs do not show 
significant proliferation defects when compared to wild type cells, which could 
reflect species- and/or cell type-specific BPTF roles. Alternatively, MEFs could 
have a distinct ability to adapt and bypass the need of BPTF.  
DNA replication requires extensive chromatin rearrangements; it is thus 
conceivable that chromatin remodelling by BPTF:NURF might contribute to this 
process via multiple mechanisms.  
Initiation of DNA synthesis takes place through a series of tightly coordinated 
events occurring from early G1 to the G1/S transition. During early G1, ORC (Origin 
Recognition Complex) proteins assemble at replication origins throughout the 
genome. The mechanisms involved therein are not well understood because 
replication origins are widely distributed and do not share a common DNA 
sequence, but epigenetic factors such nucleosome phasing and histone 
modifications are plausible candidates (McNairn and Gilbert 2003; Cohen et al. 
2010). Not all origins initiate replication, but many are licensed when the 
replicative helicases MCM2-7 are recruited in a CDC6- and CDT1-dependent 
manner (Falbo and Shen 2006). Licensed origins that fire early during S phase tend 
to have higher histone acetylation levels than those that fire later (Goren et al. 
2008; Vogelauer et al. 2002). The final step in replication initiation is the loading 
of the replicative polymerases. NURF-dependent chromatin remodelling could be 
critical to multiple steps of this process, from unmasking replication origins by 
reconfiguring the nucleosomes around them, to facilitating the loading of MCMs 
and replicative polymerases. Alternatively, NURF could interact with and facilitate 
the activity of transcription factors involved in G0/G1 or G1/S transition (e.g. E2F, 
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AP-1 or c-MYC). A role in the early steps of DNA replication has been already 
established for other chromatin remodellers such as BRG1, the catalytic subunit 
of the SWI/SNF complex, which co-localizes with proteins of the replication 
machinery (Cohen et al. 2010). 
Once replication has been initiated, the replication forks progress along the 
genome and the synthesis of new strands of DNA takes place. If DNA polymerases 
encounter a lesion, or else nucleotide pools are depleted, replication forks stall. 
Similarly to other ISWI family members (e.g. ACF or WICH), NURF could be in 
charge of keeping an open chromatin structure around replication forks and thus 
facilitate their progression (Collins et al. 2002; Poot et al. 2004). In addition, NURF 
might participate in rescuing stalled replication forks, either through their 
stabilization or the activation of checkpoint responses (Falbo and Shen 2006). 
These mechanisms remain to be experimentally addressed. 
Given the essential role of chromatin remodellers during DNA synthesis, both 
their levels and activity are subjected to tight mechanisms of control. In 
agreement with this, the experiments with human fibroblasts arrested in G0 show 
that BPTF protein levels fluctuate during the cell cycle: it is rapidly induced upon 
mitogenic stimulation and its levels drop as cells progress into S phase. BPTF re-
expression is only detected 35 hours post-release, after G2/M is completed and 
cultures become asynchronous. Additional experiments are required in order to 
confirm that BPTF protein is indeed restricted to G0-G1, such as synchronization 
of U2OS cells at the G1/S boundary or in metaphase via double-thymidine block 
or colcemid, respectively (Marqués et al. 2008).   
The changes in BPTF protein levels during cell cycle are not accompanied by 
concomitant alterations in its mRNA levels, thus suggesting that post-
translational modifications are involved. In fact, independent large scale 
proteomics studies have identified multiple residues in the BPTF sequence that 
are susceptible to phosphorylation and acetylation (Olsen et al. 2006; Matsuoka 
et al. 2007; Dephoure et al. 2008; Mayya et al. 2009; Rigbolt et al. 2011; 
Choudhary et al. 2011; Olsen et al. 2010). One example is the phosphorylation on 
S216, which has been uncovered by three studies and appears to be mutated in 
cutaneous squamous cell carcinoma (Durinck et al. 2011). In line with these 
observations, examples of both phosphorylation and acetylation of chromatin 
remodellers have been reported in the literature. Phosphorylation of the 
SWI/SNF subunits BRG1 and BAF155 by ERK1 inhibits the remodelling activity of 
the complex (Sif et al. 1998), while phosphorylation of FAC1 enhances its DNA 
binding activity (Jordan-Sciutto et al. 1999b). Also, acetylation of Drosophila ISWI 
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by the histone acetyltransferase Gcn5 controls NURF function during 
chromosome condensation (Ferreira et al. 2007).  
The roles of BPTF post-translational modifications are not yet known but they 
probably impact the half-life or the DNA-binding activity of the NURF complex. 
The generation of cell lines and, eventually, mice carrying point mutations in 
these residues using the CRISPR/Cas9 technology would provide key insights into 
BPTF function (Inui et al. 2014). Another important issue that needs to be tackled 
is the identification of the effectors of such modifications. Taking into account the 
amino acid sequence, plausible candidates are the MAPK kinases for P-Ser216 
(PRSP), and the CDK kinases for P-Ser2465 (SPVR) (Holmes and Solomon 1996; 
Songyang et al. 1996). Furthermore, and considering the expression pattern of 
BPTF during cell cycle, we could narrow down the latter to the interphase CDKs 
(2, 4 and 6) or the transcriptional CDKs (7-11) (Malumbres 2011).  
 
2. BPTF AND c-MYC AXIS 
We have shown that BPTF and c-MYC are found within the same complex in 293 
cells and that they interact in cultured cells using the isPLA assay. Unfortunately, 
and due to the lack of immunoprecipitation-grade antibodies for BPTF, we have 
not been able to conduct the co-IP with the endogenous proteins. Nonetheless, 
our experiments confirm a functional interaction between BPTF and c-MYC, since 
BPTF down-regulation in human fibroblasts transduced with MYC-ER impairs the 
transcriptional response to c-MYC activation. Several mechanisms might account 
for the attenuation of c-MYC transcriptional activity in the absence of BPTF, as 
hypothesized below:  
 
2.1. c-MYC recruitment to DNA and/or stability of the complex 
c-MYC target promoters cluster into ‘high-affinity’ or ‘low-affinity’ sites. High-
affinity targets are bound by c-MYC in different cell lines regardless of c-MYC 
levels. Conversely, low-affinity sites vary among cell types and are only engaged 
when c-MYC is expressed at high levels (Fernandez et al. 2003). The two groups 
of promoters cannot be differentiated on the basis of sequence motifs but can be 
discriminated according to their associated epigenetic marks. High-affinity 
promoters typically display higher levels of H2A.Z, H3K4/K79me, and global 
H3/H4ac. In contrast, low-affinity promoters show enrichment in macroH2A, 
H3K27me3, and H4K16ac (Guccione et al. 2006; Martinato et al. 2008).  
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We have shown that BPTF depletion impairs c-MYC-mediated transcriptional 
response. This is accompanied by a reduction in c-MYC recruitment to some, but 
not all, target promoters. For the sake of clarity we will refer to them as ‘sensitive’ 
and ‘non-sensitive’ to BPTF levels. The distinctive feature between the two 
collections of genes is the relative abundance of high-affinity targets: it is 
significantly higher in the set of ‘non-sensitive’ promoters.  
These data suggest that BPTF requirement for target recognition by c-MYC 
depends on the epigenetic context: while dispensable for c-MYC binding to 
H3K4me3-rich ‘high-affinity’ promoters, it might participate in the recognition of 
low-affinity sequences, presumably through H4K16ac. An alternative explanation 
is that BPTF-mediated chromatin remodelling stabilizes the association of c-MYC 
with low-affinity promoters. There are indeed precedents in the literature for 
chromatin remodellers securing the binding of transcription factors to their 
cognate sites in the genome. For instance, stable binding of MyoD, a key regulator 
of muscle differentiation, requires the recruitment of the remodelling complex 
SWI/SNF (de la Serna et al. 2005). Alternative mechanisms may also contribute to 
explain these observations. 
The impact of BPTF silencing on c-MYC recruitment to distal enhancer elements 
remains to be determined. Active enhancers are characterized by high H3K4me1-
2, H3K27ac, recruitment of the HAT p300, and the presence of transcription 
factor binding motifs and DNAse I hypersensitivity sites (Heintzman et al. 2007; 
Krebs et al. 2011; Smallwood and Ren 2013). The C-terminal PHD finger of BPTF 
shows a predilection for H3K4me3 but can also bind H3K4me2 (Ruthenburg et al. 
2011). It is thus possible that the NURF complex is recruited to enhancers through 
the recognition of H3K4me2, along with other chromatin remodellers such as 
CHD7 and BRG1 (Schnetz et al. 2010; Rada-Iglesias et al. 2011).  
 
2.2. Remodelling of c-MYC target chromatin 
BPTF silencing also dampens the transcriptional response of ‘non-sensitive’ 
promoters. The impact of BPTF knock-down on these genes is likely due to a 
defective chromatin remodelling at their promoters, as suggested by the fact that 
BPTF silencing blocks the increase in DNA accessibility at c-MYC promoters 
typically linked to c-MYC activation. The putative mechanisms accounting for such 
observation are discussed henceforth.  
c-MYC recruits the chromatin remodeller SWI/SNF (Cheng et al. 1999), whose 
activity is partially inhibited by the linker histone H1 (Hill and Imbalzano 2000, 
Ramachandran et al. 2003). Moreover, NURF is necessary for H1 displacement at 
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the promoters of progesterone receptor target genes (Vicent et al. 2011). We 
could hypothesize that NURF-mediated eviction of H1 at c-MYC-bound promoters 
is a pre-requisite for subsequent remodelling and nucleosome eviction by the 
SWI/SNF complex.  
BPTF binds H3K4me3 through its PHD domains but does not appear to affect the 
levels of this histone modification at c-MYC target promoters. By contrast, BPTF 
silencing reduces the hyper-acetylation of H3, commonly associated to c-MYC 
activation (Martinato et al. 2008). These data suggest that BPTF, either on its own 
or through its interaction with c-MYC, is required to recruit and/or modulate the 
activity of HATs at relevant promoters. In fact, there is evidence of the latter in 
Drosophila, where Nurf301 is needed for the histone acetyl-transferase ATAC to 
access chromatin and maintain the condensed architecture of the male X 
chromosome (Carré et al. 2008). A putative role on histone deacetylases cannot 
be ruled out.  
 
2.3. Long-range interactions 
The organization of eukaryotic genomes in the 3D nuclear space is determinant 
of their function. Chromosome conformation capture techniques have shown 
that genomes are organized into thousands of topologically associating domains 
(TADs) (Dixon et al. 2012). TADs demarcate active and repressed regions of the 
genome and typically contain tens of genes and hundreds of enhancers. They 
show a high degree of conservation between cell types and species, suggesting 
that physical partitioning of the genome is a fundamental principle of genome 
organization (Smallwood and Ren 2013). Regulatory elements display extensive 
long-range interactions within a TAD but interact far less frequently with 
elements located outside (Sanyal et al. 2012; Shen et al. 2012).  
In vertebrates, this organization is partly established by the architectural 
proteins CTCF (CCCTC-binding factor) and TFIIIC (Ong and Corces 2014). 
Transcriptional activity might also play a role since the boundaries of topological 
domains are enriched in highly transcribed sequences including housekeeping 
genes, tRNAs and SINE elements (Hou et al. 2012; Dixon et al. 2012) (Fig. 28). Such 
boundaries allow the coordinated regulation of gene expression within TADs, 
contain repressive regions and segregate antagonistic elements.  
Inside TADs, long and short-range interactions are established between cis-
regulatory sequences and promoters in order to modulate transcription. The 
chromatin loops originating from such interactions place promoters and 
enhancers in close proximity and thus favour transcription. The way chromatin 
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looping alters transcriptional output is not yet understood, but it might enhance 
RNA Pol II recycling, mRNA export and recruitment of remodelling and histone 
modification complexes (Maksimenko and Georgiev 2014). Moreover, enhancer-
promoter pairs may move to a more favourable transcriptional compartment 
within the nucleus (Krivega and Dean 2012). These chromatin loops are 
orchestrated by sequence-specific transcription factors, CTCF, Cohesin1, and 
Mediator, either alone or in various combinations (Fig. 28). 
                                                          
1 COHESIN: Multiprotein complex that forms a ring-like structure which holds together 
two DNA helices and is critical for sister chromatid cohesion (Nasmyth and Haering 
2009). Strong evidence indicates that, besides its role in mitosis and meiosis, cohesin 
regulates transcriptional activity during interphase (Merkenschlager and Odom 2013). 
 
Figure 28. Spatial organization of the eukaryotic genome. (Top) Schematic data 
generated by Hi-C representing an interaction heat map of a chromosome segment. 
(Bottom) TAD borders are established by the cooperative action of CTCF, TFIIIC and 
Cohesin. Within TADs, CTCF facilitates enhancer-promoter looping and plays an 
essential role in controlling gene expression (Erokhin et al. 2011). One mechanism is 
through the interaction with TAF3, a component of the basal TFIID transcriptional 
machinery. TAF3 localizes at promoters and distal sites containing CTCF, and both 
sequences form a loop in a TAF3-dependent manner (Liu et al. 2011). CTCF recruits 
Cohesin, which stabilizes the enhancer-promoter DNA loops built by CTCF, transcription 
factors and mediator (Kagey et al. 2010; Schmidt et al. 2010; Yan et al. 2013; Smallwood 
and Ren 2013). Adapted from Ong and Corces 2014. 
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There is ample evidence suggesting the involvement of BPTF in the organization 
of long-range chromatin interactions. First, it interacts with Drosophila GAGA 
Factor and USF1, two proteins with insulator properties, and it is critical for the 
function of the 5’HS4 insulator (Xiao et al. 2001; Li et al. 2011). Second, it binds 
to the architectural proteins CTCF and STAG2 and regulates nucleosomal 
occupancy at genomic sites occupied by both proteins (Qiu et al. 2015). Lastly, 
BPTF has been involved in the establishment/maintenance of the interactions 
between the enhancers of olfactory receptor genes (Markenscoff-Papadimitriou 
et al. 2014).  
 
Altogether, we can speculate that BPTF participates in the control of gene 
expression by enhancing the interplay between promoters and other cis-
regulatory sequences. Multiple mechanisms might account for such function: on 
one hand, BPTF could facilitate the recruitment of sequence-specific transcription 
factors to enhancers and regulatory elements in cis; alternatively, BPTF could play 
a more architectural role, assisting the formation of chromatin loops along with 
CTCF and STAG2. By extension, BPTF could facilitate c-MYC ‘invasion’ of distal 
Figure 29. Mechanisms of control of c-MYC transcriptional activity by BPTF. BPTF 
enhances c-MYC-dependent transcriptional activation through a wide range of 
mechanisms. First, it participates in the recruitment and/or stabilization of c-MYC onto 
gene promoters via recognition of the histone marks H3K4me3 and H4K16ac. Second, 
it contributes to the remodelling of chromatin at c-MYC target promoters; either by 
altering nucleosome positioning or by recruiting/modulating the activity of HATs. 
Moreover, BPTF may also be involved in the formation of DNA loops between c-MYC 
target enhancers and promoters. One possible mechanism could be the recruitment of 
c-MYC to enhancer sequences through the recognition of H3K4me2. Alternatively, BPTF 
would stabilize the enhancer-promoter pairs in collaboration with CTCF and STAG2. 
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enhancer elements (Lin et al. 2012; Sabò et al. 2014) and boost transcription by 
helping to build the DNA loops between c-MYC target enhancers and promoters 
(Fig. 29). 
 
2.4. Transcription elongation 
Among other mechanisms, c-MYC enhances gene transcription by recruiting P-
TEFb and promoting RNA Pol II pause-release (Rahl et al. 2010; Cowling and Cole 
2006). We could also speculate that BPTF:NURF plays a role in transcription 
elongation, since the yeast chromatin remodelling complex Iswi has been found 
in gene bodies, where it coordinates RNA Pol II elongation, termination and pre-
mRNA processing (Morillon et al. 2003; Zentner et al. 2013). 
 
2.5. Repression by c-MYC 
The effects of BPTF silencing on the output of c-MYC transcriptional activity 
involve not only genes whose expression is up-regulated but also those that are 
down-regulated. The mechanisms involved in "repression" by c-MYC are a highly 
debated topic (Lovén et al. 2012). Chromatin remodelling complexes can repress 
gene transcription by restricting the access to DNA (Morillon et al. 2003) or by 
removing DNA-binding factors required for transcriptional activation. In this 
regard, the yeast Isw1 complex displaces TBP from the PHO8 promoter and 
effectively inhibits basal transcription (Moreau et al. 2003). Alternatively, 
chromatin remodellers associate with chromatin modifiers that help enforce 
repression. This is the case of Drosophila ISWI, which interacts with the HDAC 
RPD3 to inhibit gene expression (Burgio et al. 2008). 
 
Identification of BPTF target sequences will significantly improve our 
understanding of the mechanisms whereby it modulates c-MYC transcriptional 
activity. So far, the lack of ChIP-grade antibodies has rendered this task 
unfeasible. Vicent et al. have published the only ChIP-Sequencing experiment 
against endogenous BPTF to date using a home-made antibody that is no longer 
available. Interestingly, in their study 40.8% of BPTF peaks were located in introns 
and only 5% fell into promoter regions, further supporting the hypothesis that 






3. BPTF IN DEVELOPMENT AND DIFFERENTIATION 
Extensive evidence indicates that chromatin remodellers play decisive roles in 
regulating gene expression during development. They not only regulate the 
global body plan but they also contribute to tissue specification and maintenance 
of stem cell compartments in the adult (Clapier and Cairns 2009).  
 
3.1. Early embryonic development 
BPTF is essential for the embryonic development of different animal species. 
Mutation of Drosophila Nurf301 results in lethality at the third larval stage and 
deregulation of homeobox, heat shock, JAK/STAT and ecdysone pathways 
(Badenhorst et al. 2002; Deuring et al. 2000). Similarly, Nurf301 knock-down at 
the 2 cell stage of Xenopus is associated with defective axial development, gut 
formation, blood cell development and expression of homeobox genes (Wysocka 
et al. 2006). In this regard, BPTF-deficient mouse embryos fail to develop the 
ectoplacental cone and show defective AP patterning of the epiblast (Landry et 
al. 2008; Goller et al. 2008). c-Myc null mouse embryos also exhibit severe 
developmental defects and die before midgestation. These abnormalities arise 
secondary to placental insufficiency, since specific deletion of c-MYC in the 
epiblast using a Sox2-Cre rescues the majority of developmental anomalies. 
Epiblast-restricted c-Myc knock-out embryos progress normally but die around 
E12 due to a severe anemia (Dubois et al. 2008).  
 
3.2. Cell differentiation 
There is little information on NURF function in adult mouse tissues. So far, NURF 
has been proven to be required for the full maturation of thymocytes after 
positive selection: BPTF deletion impairs differentiation without interfering with 
proliferation, apoptosis or co-receptor expression (Landry et al. 2011). There are 
some hints, as well, suggesting that BPTF participates in the homeostasis of 
epidermis, since its down-regulation in human keratinocytes favours their 
differentiation (Mulder et al. 2012).  
As a step towards the understanding the role of BPTF in c-MYC-driven 
tumorigenesis, we have developed two mouse models to conditionally delete 
Bptf in the pancreas and in B cells, both tissues showing a dependence on c-MYC 
for their full development. c-MYC inactivation in pancreatic progenitors is 
associated with impaired growth, defective acinar cell maturation and 
accumulation of adipocytes with time (Bonal et al. 2009). Similarly, depletion of 
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c-MYC in early stages of B cell maturation results in impaired activation of lineage-
specifying genes and a blockade of differentiation (Habib et al. 2007; Vallespinós 
et al. 2011; Calado et al. 2012). Importantly, BPTF inactivation had strikingly 
different results in the two tissues: while having no evident impact on pancreatic 
development or differentiation, it completely abrogated B cell differentiation. 
BPTF and B cell differentiation. B cells constitute an excellent model to study 
differentiation since the generation of mature B cells proceeds through well-
defined stages with critical checkpoints that have been extensively examined. 
Each stage is characterized by the expression of a unique combination of surface 
molecules that can be readily assessed by flow cytometry (Fig. 30).  
 
We have conditionally deleted Bptf in the mouse B cell lineage (BptfB) using 
the Mb1-Cre allele (Hobeika et al. 2006), which becomes active at the earliest 
steps of B cell development, and shown successful recombination by genomic 
PCR analysis of bone marrow (BM) B220+ cells (Fig. 31a). Spleens of BptfB mice 
are significantly smaller than their wild-type counterparts, what is suggestive of 
impaired B cell maturation (Fig. 31b). In agreement with this, flow cytometry 
analyses of both spleen and BM revealed that, upon loss of BPTF, B cell 
development is blocked at the pro- to pre-B cell transition. Pre-pro B and Pro-B 
cells (B220low; IgM−; CD43+) accumulate in the BM of mutant animals, while pre-
B cells (B220low;IgM−;CD43-) are significantly reduced. Immature (B220low; IgM+) 
and mature B cells (B220high; IgM+) are virtually absent in BptfB mice (Fig. 31c).  
Annexin V staining has shown similar levels of apoptosis in pre-pro and pro-B cells 
of WT vs. BptfB mice (25.7 vs. 21.6%); by contrast, the number of apoptotic cells 
is significantly increased in pre-B cells of BptfB mice (66.2% vs. 29.9%). These 
data indicate that BPTF is necessary for pre-B cell survival and is therefore 
required from early stages of B cell differentiation. Whether BPTF is dispensable 
at later stages of B cell development is an open question. For this purpose, we 
propose to breed Bptffl/fl conditional mice with Mx-Cre transgenic mice, where 
Figure 30. B lymphocyte differentiation. Successive stages of differentiation from 
the HSC (Hematopoietic Stem Cells) and CLP (Common Lymphoid Progenitors) cells. 
Key cell-surface markers are shown. Adapted from Fernandez et al. 2012. 
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Cre recombinase is induced upon injection of IFN or pIpC (Hobeika et al. 2006; 
Vallespinós et al. 2011).   
 
Figure 31. BPTF is required for B cell differentiation from early stages. a) Genomic PCR 
analysis of wt, floxed and recombined Bptf alleles from sorted B220+ and B220- BM cells 
from the indicated mouse genotypes. b) Top: Representative picture of spleens from 8-
10 weeks-old Mb1-Cre+/KI mice of the indicated genotypes showing a significant 
reduction in spleen size upon Bptf depletion. Bottom: Spleen weight in grams and in % 
of body weight of mice in the upper panel. c) FACS analysis of B cell populations in BM 
and spleen from Mb1-Cre+/KI mice of the indicated genotypes. Deletion of BPTF in B cells 
lineage leads to a reduction in the pre-B, immature B, and mature B cell compartments 
in both BM and spleen. d) BM single cell suspensions were stained with Annexin V and 
the same markers as in c. Upon BPTF depletion, we detect increased apoptosis in the 
compartment of pre-B cells. 
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Interestingly, the phenotype of BptfB mice is reminiscent of that of c-Myclox/lox; 
Mb1-Cre+/KI mice (Vallespinós et al. 2011), suggesting that it could partially arise 
from faulty c-MYC transcriptional activity. EBF-1 is a c-MYC target and a critical 
transcription factor in early B cell maturation and its overexpression rescues the 
differentiation defects of c-Myc B cells (Vallespinós et al. 2011). Therefore, 
overexpressing c-MYC or EBF-1 in Bptf B lymphocytes and subsequently 
assessing their differentiation status would shed light on the mechanisms 
involved therein. An alternative explanation to the blockade in B cell 
differentiation is that BPTF is required for the productive rearrangement of the 
immunoglobulin genes, a bottleneck in B lymphocytes maturation. 
Other chromatin remodellers that cooperate with transcription factors in 
activating genes necessary for B cell commitment, survival and proliferation are 
Srg3/mBaf155 (Choi et al. 2012), a core subunit of the SWI/SNF-like BAF complex, 
and Brg1 (Holley et al. 2014). The distinct phenotypes observed upon NURF or 
SWI/SNF inactivation suggest that chromatin remodellers have specific and non-
overlapping roles during B cell differentiation. 
 
In summary, the tissue-specific functions of the NURF complex call for a more 
detailed assessment of its role in different cell types. We are currently breeding 
the Bptffl/fl conditional mouse with UBC-Cre-ERT2 (Ruzankina et al. 2007) and 
Krt5-Cre mice (Tarutani et al. 1997) to begin exploring these questions. 
 
4. BPTF AND TUMORIGENESIS 
Cancer research has identified six capabilities acquired by malignant cells that 
enable tumor growth and metastatic dissemination: continuous proliferative 
signaling, insensitivity to growth-inhibitory signals, resistance to cell death, 
replicative immortality, sustained angiogenesis and tissue invasion (Hanahan and 
Weinberg 2011). Increasing evidence suggests that alterations in epigenetic 
processes (e.g. chromatin remodelling, histone modifications or DNA 
methylation) can result in genomic instability, DNA damage and transcriptional 
changes and hence contribute to the acquisition of such features. Inactivating 
mutations in genes encoding the catalytic and regulatory subunits of the SWI/SNF 
complex have been detected in several human cancers: bi-allelic loss of SNF5 
occurs in most malignant rhabdoid tumors and some epithelioid sarcomas, while 
BRG1 gene is lost in cancer cell lines of multiple origins (Versteege et al. 1998; 
Helming et al. 2014). 
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Early work in Drosophila showed that deletion of Nurf301 is associated with 
neoplastic transformation of circulating blood cells, leading to the formation of 
inflammatory or melanotic tumors (Kwon et al. 2008). In C. elegans, inhibition of 
ISWI function suppresses the defects associated with loss of the tumor 
suppressor lin-35 Rb or the activation of oncogenic let-60 Ras (Andersen et al. 
2006). More recently, mutations in BPTF have been found in several tumor types 
(Fujimoto et al. 2012; Balbás-Martínez et al. 2013; González-Pérez et al. 2013; 
Xiao et al. 2014a). The impact of such mutations has not been analysed in detail 
yet due to the size of the protein and little knowledge of its biological roles. 
Nonetheless, and according to the data integrated in IntOGen, 10% of the 
mutations reported so far are truncating and cold give rise to BPTF fragments 
with dominant negative properties (Gundem et al. 2010). Moreover, high BPTF 
levels have been reported to be associated with poor prognosis and invasiveness 
in hepatocellular carcinoma, melanoma and colorectal carcinoma (Xiao et al. 
2014b; Xiao et al. 2015; Dar et al. 2015). These findings suggest that BPTF may 
play an important role in tumorigenesis and therefore it constitutes an attractive 
candidate for drug targeting in cancer therapy. There are indeed precedents in 
the literature for inhibition of chromatin remodellers as successful cancer 
therapeutic strategies. One example is Brd4, whose inhibition has been proven 
successful in c-MYC-driven experimental models of hematologic malignancies 
(Dawson et al. 2011; Delmore et 
al. 2011; Mertz et al. 2011). 
Until now, however, the power 
of genetic mouse models of 
cancer has not been exploited to 
assess the role of BPTF in tumor 
formation and/or maintenance. 
As a proof of concept, we set out 
to explore this notion using two 
mouse models of highly 
aggressive c-MYC-driven tumors: 
the Ela-Myc and the E-Myc.  
We have preliminary data 
suggesting that inactivation of 
Bptf in the pancreas of adult Ela-
Myc mice inhibits the formation 
of pancreatic tumors. Moreover, 
Figure 31. BPTF loss delays tumor onset in a 
murine model of Burkitt lymphoma. In E-
Myc mice, c-MYC is overexpressed in the B cell 
lineage under the control of the IgH enhancer. 
These mice develop spontaneous pre-B and B 
cell lymphomas at 15-20 weeks of age. This 
graph depicts the Kaplan-Meier curves of 
tumor-free survival for E-Myc mice of the 
indicated Bptf genotypes. P-value was 
calculated with the log-rank test. 
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inactivation of only one Bptf allele has no major impact on B cell maturation but 
is sufficient to block the formation of c-MYC-driven B cell lymphomas (Fig. 31). 
These promising results highlight the relevance of the c-MYC:BPTF axis as a target 
for cancer therapy. A more detailed molecular, structural, and functional 
dissection of BPTF will allow the development of therapeutic strategies exploiting 
its function in cancer. One strategy could consist of disrupting the interaction 
between the two proteins. Alternatively, drugs could be designed specifically 
targeting the BPTF bromodomain. 
 
The biochemical properties of the NURF:BPTF complex have been well 
characterized, but the importance of its function in mammals has just begun to 
emerge. Here we have provided some key insights into BPTF function, although 
many important questions remain to be answered (Box 1). First, we have unveiled 
the interaction with the oncogene c-MYC. This observation could lead to a new 
field of research by itself and raises the possibility of developing new anti-cancer 
strategies. We have also assessed BPTF role in adult tissue homeostasis and 
shown that, while dispensable for formation of the pancreas, it is crucial for the 
maturation of B cells. In addition, we have preliminary data suggesting that it 
plays a critical role in tumorigenesis. In conclusion, we provide strong evidence 
that BPTF is an important protein involved in chromatin remodelling required for 
the action of c-MYC that merits additional study. Unravelling the molecular 










   
 
1. Is Nurf301/BPTF exclusive to the NURF complex? It will be essential to 
determine if BPTF only works as a component of the NURF complex, or rather, it 
has ATPase-independent functions. We find a precedent for this in Brg1, which has 
been proven to have gene regulatory functions separate from its ATPase activity 
(Jani et al. 2008).   
2. How is NURF function regulated? The activity of chromatin remodelling 
complexes can be modulated by alterations in their subunit composition (Lessard 
et al. 2007) or alternative splicing events. Drosophila NURF is an example of the 
latter. The gene nurf301 gives rise to three distinct isoforms by alternative splicing, 
one of them lacking the C-terminal domains involved in the recognition of 
H3K4me3 and H4K16ac. Interestingly, full-length Nurf301 is not essential for the 
correct expression of most NURF targets, with the exception of genes related to 
spermatogenesis (Kwon et al. 2009). The existence of an isoform with similar 
properties in mammalian cells remains unknown. 
3. Which are the direct targets of NURF in vivo? Genome-wide mapping of NURF 
localization coupled to high-throughput methods assessing changes in chromatin 
structure upon Bptf/Nurf301 knockout will help to identify these sites. 
4. What are the transcription factors BPTF interacts with in human cells? The 
development of high-quality immunoprecipitating antibody would facilitate the 
identification of BPTF interactome using immunoprecipitation and mass-
spectrometry-based analysis.  
5. Does BPTF participate in the DNA damage response? Bptf is phosphorylated in 
response to activation of the ATM/ATR pathway (Matsuoka et al. 2007), thus 
suggesting that it could play a role in the DNA damage response. We can find 
examples in the literature of chromatin remodelling complexes that participate in 
such pathway. For instance, INO80 is phosphorylated by the Mec1/Tel1 kinases 
that coordinate the DNA damage response and is recruited to DSBs (Double Strand 
Breaks) marked by -H2AX (Morrison et al. 2007). 









1. BPTF is a component of the NURF complex playing a critical role in the 
proliferation of normal and cancer cells. Its knock-down in human fibroblasts 
blocks S phase entry.  
2. BPTF levels are modulated during cell cycle progression: in human fibroblasts, 
it is induced upon entry into G1 and is down-regulated in S phase.  
3. Using a combination of biochemical assays we demonstrate that BPTF and c-
MYC are found within the same protein complex and that they interact directly. 
4. In human fibroblasts transduced with the MYC-ER fusion protein, BPTF is 
required for the activation of the full c-MYC transcriptional program through 
chromatin remodelling of its target promoters. 
5. In MEFs transduced with Myc-ER, BPTF is necessary for c-MYC-driven 
proliferation but not for apoptosis, suggesting that BPTF is only required for those 
c-MYC functions involving direct binding to chromatin. 
6. BPTF is necessary for the reprogramming of murine fibroblasts into induced 
pluripotent stem cells. 
7. BPTF is expressed at high levels in human tumors of diverse origin. Its 
expression positively correlates with the activation of c-MYC, but not N-MYC or 
L-MYC, driven gene signatures. 
8. BPTF has tissue-specific roles in cell differentiation: while dispensable for the 
formation of the mouse pancreas, it is crucial for the generation of mature B cells 
in bone marrow and spleen. 
9. Preliminary data indicate that, in mice, BPTF plays a critical function in the 









1. BPTF es un componente del complejo NURF con un papel crítico en la 
proliferación de células normales y cancerosas. Su knock-down en fibroblastos 
humanos resulta en un bloqueo en la entrada en fase S.  
2. Los niveles de BPTF son modulados durante la progresión del ciclo celular: en 
fibroblastos humanos, BPTF es inducido al entrar las células en G1 y se down-
regula en fase S. 
3. Por medio de una combinación de ensayos bioquímicos hemos demostrado 
que BPTF y c-MYC se encuentran en el mismo complejo proteico y que 
interaccionan directamente. 
4. En fibroblastos humanos transducidos con la proteína de fusión MYC-ER, BPTF 
es requerido para la activación completa del programa transcripcional de c-MYC 
a través de la remodelación de la cromatina en sus promotores diana. 
5. En fibroblastos embrionarios de ratón transducidos con MYC-ER, BPTF es 
necesario para la proliferación inducida por c-MYC, pero no para la apoptosis 
dirigida por este oncogén, sugiriendo que BPTF solo es necesario para aquellas 
funciones de c-MYC que implican la unión directa a la cromatina. 
6. BPTF es necesario para la reprogramación de fibroblastos de ratón a células 
madre de pluripotencia inducida. 
7. BPTF se expresa a niveles altos en diversos tipos de tumores humanos. Su 
expresión correlaciona positivamente con la activación de programas de 
expresión génica instruidos por c-MYC, pero no por N-MYC o L-MYC. 
8. BPTF tiene funciones tejido-específicas en diferenciación celular: mientras que 
es dispensable para la formación del páncreas de ratón, es crucial para la 
generación de células B maduras en la médula ósea y bazo. 
9. Datos preliminares sugieren que, en ratones, BPTF juega un papel crítico en la 
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